WO2023008427A1 - 慢性肝疾患における肝発癌の診断マーカー - Google Patents
慢性肝疾患における肝発癌の診断マーカー Download PDFInfo
- Publication number
- WO2023008427A1 WO2023008427A1 PCT/JP2022/028776 JP2022028776W WO2023008427A1 WO 2023008427 A1 WO2023008427 A1 WO 2023008427A1 JP 2022028776 W JP2022028776 W JP 2022028776W WO 2023008427 A1 WO2023008427 A1 WO 2023008427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gdf15
- liver cancer
- subject
- risk
- level
- Prior art date
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 299
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 298
- 238000011161 development Methods 0.000 title abstract description 34
- 206010073069 Hepatic cancer Diseases 0.000 title abstract 5
- 208000019423 liver disease Diseases 0.000 title description 48
- 239000003550 marker Substances 0.000 title description 11
- 230000001684 chronic effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 102
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims abstract description 36
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims abstract 28
- 210000002966 serum Anatomy 0.000 claims description 113
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 103
- 241000711549 Hepacivirus C Species 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 29
- 208000002672 hepatitis B Diseases 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 10
- 238000007619 statistical method Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 210000005228 liver tissue Anatomy 0.000 claims description 7
- 239000000090 biomarker Substances 0.000 claims description 6
- 230000002459 sustained effect Effects 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 abstract description 6
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 description 263
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 263
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 75
- 208000005176 Hepatitis C Diseases 0.000 description 49
- 230000001186 cumulative effect Effects 0.000 description 39
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 39
- 208000005623 Carcinogenesis Diseases 0.000 description 26
- 230000036952 cancer formation Effects 0.000 description 26
- 231100000504 carcinogenesis Toxicity 0.000 description 26
- 229940125371 direct-acting antiviral drugs Drugs 0.000 description 23
- 238000009795 derivation Methods 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 208000010706 fatty liver disease Diseases 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 238000013517 stratification Methods 0.000 description 14
- 238000010200 validation analysis Methods 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 241000700721 Hepatitis B virus Species 0.000 description 13
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 13
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 230000004730 hepatocarcinogenesis Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 206010016654 Fibrosis Diseases 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 102000046181 human GDF15 Human genes 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- -1 Fib4 Proteins 0.000 description 7
- 238000013211 curve analysis Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000101 novel biomarker Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000009589 serological test Methods 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- 206010019837 Hepatocellular injury Diseases 0.000 description 4
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 4
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 201000001862 viral hepatitis Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 231100001223 noncarcinogenic Toxicity 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007473 univariate analysis Methods 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 231100000437 hepatocellular injury Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000023768 LCAT deficiency Diseases 0.000 description 1
- 208000003465 Lecithin Cholesterol Acyltransferase Deficiency Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 244000025012 Spondias pinnata Species 0.000 description 1
- 235000005658 Spondias pinnata Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229960002118 asunaprevir Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960005449 daclatasvir Drugs 0.000 description 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940072240 direct acting antivirals Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- SVPWXLXHFSKQRN-QZUDGTEMSA-N elbasvir and grazoprevir Chemical compound O=C([C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCC1=NC3=CC=C(C=C3N=C1O2)OC)C(C)(C)C)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C1N=C(C=2C=C3O[C@H](N4C5=CC=C(C=C5C=C4C3=CC=2)C=2NC(=NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)C=2C=CC=CC=2)C=N1 SVPWXLXHFSKQRN-QZUDGTEMSA-N 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 230000004769 mitochondrial stress Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229960000518 ombitasvir Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- UAUIUKWPKRJZJV-MDJGTQRPSA-N paritaprevir Chemical compound C1=NC(C)=CN=C1C(=O)N[C@@H]1C(=O)N2C[C@H](OC=3C4=CC=CC=C4C4=CC=CC=C4N=3)C[C@H]2C(=O)N[C@]2(C(=O)NS(=O)(=O)C3CC3)C[C@@H]2\C=C/CCCCC1 UAUIUKWPKRJZJV-MDJGTQRPSA-N 0.000 description 1
- 229960002754 paritaprevir Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229960002063 sofosbuvir Drugs 0.000 description 1
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 description 1
- 229940118849 sofosbuvir and ledipasvir Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention relates to a method for evaluating the risk of developing a disease using a diagnostic marker for the disease, and specifically to a method for evaluating the risk of developing hepatocarcinogenesis in chronic liver disease.
- Non-Patent Documents 1 and 2 Various chronic liver diseases such as chronic hepatitis B and C, and non-alcoholic steatohepatitis cause liver cancer.
- Chronic liver disease is classified into viral chronic liver disease and non-viral chronic liver disease.
- Viral chronic liver disease is mainly classified into hepatitis C caused by the hepatitis C virus and hepatitis B caused by the hepatitis B virus.
- Non-viral chronic liver disease is classified into fatty liver disease and autoimmune liver disease.
- Hepatitis C With the advent of direct-acting antivirals (hereinafter referred to as "DAAs"), new therapeutic agents for hepatitis C, the hepatitis C virus (HCV) has been eliminated in many cases. became. After elimination of the hepatitis C virus, there is a risk of hepatic carcinogenesis, precisely, liver cancer even after achieving sustained virological response (hereinafter referred to as "SVR”) (Non-Patent Document 5). In many cases of hepatitis C, regular imaging and blood tests are performed after treatment has ended.
- DAAs direct-acting antivirals
- Hepatitis B HBs antigen-positive patients are estimated to be about 296 million people worldwide as of 2019, and about 820,000 people die annually from cirrhosis and liver cancer caused by hepatitis B virus (HBV).
- HBV hepatitis B virus
- NUC nucleic acid analogues
- cases of carcinogenesis are observed even in cases of low HBV DNA levels.
- the incidence of liver cancer after HBs antigen disappearance is 0.0368/year.
- the incidence of liver cancer in HBs antigen persistently positive cases is 0.1957/year, and the incidence of liver cancer is significantly high (Non-Patent Document 10).
- Factors that increase the risk of carcinogenesis include age (40 years or older), gender (male), high viral load, alcohol drinkers, family history of liver cancer, co-infection with HCV, HDV and/or HIV, progression of liver fibrosis, and liver fibrosis. reduction in platelet count, genotype C, core promoter mutation, etc., which reflect the progression of dysplasia (Non-Patent Document 11).
- Non-Patent Document 11 Non-Patent Document 11
- Fatty liver disease refers to a disease in which fat accumulates in 5% or more of hepatocytes.
- Fatty liver disease is further classified into nonalcoholic fatty liver disease (NAFLD) and secondary fatty liver.
- NAFLD nonalcoholic fatty liver disease
- non-alcoholic means that the drinking amount is converted to ethanol and is less than 30 g/day for men and less than 20 g/day for women.
- NAFLD is further classified into nonalcoholic fatty liver (NAFL) histologically without hepatocellular damage and nonalcoholic steatohepatitis (NASH) histologically with hepatocellular damage and inflammation.
- NAFL nonalcoholic fatty liver
- NASH nonalcoholic steatohepatitis
- Secondary fatty liver is alcoholic, drug-induced (amiodarone, methotrexate, tamoxifen, steroids, valproic acid, antiretroviral drugs, etc.), disease-related (hepatitis C (genotype 3), Wilson's disease, lipodystrophy, starvation). , parenteral nutrition, Reye syndrome, acute fatty liver of pregnancy, HELLP syndrome), congenital metabolic disorders (a ⁇ -lipoproteinemia, hemochromatosis, ⁇ 1-antitrypsin deficiency, lecithin-cholesterol acyltransferase deficiency, lysosome production) lipase deficiency, etc.) and others (after pancreaticoduodenectomy).
- Non-Patent Documents 12 and 13 As a result of comparative examination of prognosis, it has been reported that whether or not fibrosis progresses is more important for prognosis than whether it is NAFL or NASH (Non-Patent Document 14). From another prognostic comparison study, there is also a report that patients with advanced hepatic fibrosis have a poor prognosis (Non-Patent Document 15). From the results of studies on the etiology of primary liver cancer in Japan from 1995 to 2015, it has been clarified that hepatocarcinogenesis is increasing against the background of non-viral liver disease (Non-Patent Document 16).
- FIB-4 index As well as a marker for predicting the development of liver cancer from non-viral liver disease has been reported (Gastroenterology. 2018 Dec;155(6):1828-1837.e2), but its diagnostic ability is not sufficient. , further stratification techniques are needed.
- Non-Patent Document 17 Oxidative stress induces C>A/G>T gene mutation (Non-Patent Document 17), and this mutation pattern is observed at a higher rate in liver cancer than in other cancers (Non-Patent Document 18).
- Growth Differentiation Factor 15 belongs to the TGF- ⁇ superfamily, and its expression increases in response to oxidative stress and mitochondrial stress (Non-Patent Documents 19-22).
- GDF15 is elevated in advanced hepatic fibrosis cases, and high GDF15 levels are reported to be a poor prognostic factor in liver cancer cases (Non-Patent Document 23).
- Non-Patent Document 1 Sagnelli E, et al. Infection. 2020 Feb;48(1):7-17.
- Non-Patent Document 2 Zhang CH, et al. Liver Int. 2022 doi: 10.1111/liv.15251.
- Non-Patent Document 3 Hikita H, et al. J Hepatol. 2012 Jul;57(1):92-100.
- Non-Patent Document 4 Hikita H, et al. Cancer Prev Res (Phila). 2015 Aug;8(8):693-701.
- Non-Patent Document 5 Janjua NZ et al., J Hepatol 2017;66:504-513.
- Non-Patent Document 6 Watanabe T et al., J Med Virol 2020;92:3507-3515.
- Non-Patent Document 7 Kanwal F, Singal AG, Gastroenterology 2019;157:54-64.
- Non-Patent Document 8 Nagata H et al., J Hepatol 2017;67:933-939.
- Non-Patent Document 9 Liaw YF, et al. N Engl J Med. 2004;351:1521-1531.
- Non-Patent Document 10 Simonetti J, et al. Hepatology. 2010;51:1531-1537.
- Non-Patent Document 11 Yim HJ, Lok AS.
- Non-Patent Document 12 Tokushige, K, et al. Hepatology Research.2021;51:1013-1025.
- Non-Patent Document 13 Yoshiji, H. et al. J Gastroenterol, 2021;56:593-619.
- Non-Patent Document 14 Angulo P, et al. Gastroenterology. 2015;149:389-97.
- Non-Patent Document 15 Hagstrom H, et al. J Hepatol. 2017;67:1265-1273.
- Non-Patent Document 16 Tateishi R, et al. J Gastroenterol. 2019;54:367-376.
- Non-Patent Document 17 van Loon B, et al. DNA Repair (Amst) 2010;9:604-16
- Non-Patent Document 18 Guichard C, et al. Nat Genet 2012;44:694-8.
- Non-Patent Document 19 Han ES, et al. Physiol Genomics. 2008;34:112-26.
- Non-Patent Document 20 Tsai VWW et al., Cell Metab 2018;28:353-368.
- Non-Patent Document 21 Kim J et al., Nat Metab 2021;3:410-427.
- Non-Patent Document 22 Kang SG et al., iScience 2021;24:102181
- Non-Patent Document 23 Myojin Y et al., Gastroenterology 2021;160:1741-1754.
- the purpose of the present invention is to provide a novel biomarker that predicts the development of liver cancer from chronic liver disease.
- Further objects of the present invention include hepatocarcinogenesis after SVR in hepatitis C, hepatocarcinogenesis under NUC administration in hepatitis B, and hepatocarcinogenesis from NAFLD, comprising said novel biomarkers,
- hepatocarcinogenesis after SVR in hepatitis C hepatocarcinogenesis under NUC administration in hepatitis B
- hepatocarcinogenesis from NAFLD comprising said novel biomarkers
- the present inventors proceeded with studies to achieve the above object, and discovered that the level of GDF15 protein in serum or the level of GDF15 transcripts in liver tissue can predict carcinogenesis from chronic liver disease, and thus completed the present invention. Completed.
- the present invention provides a method for evaluating a subject's risk of developing liver cancer.
- the method of the present invention comprises: (1) measuring the subject's GDF15 level; (2) A step of associating the GDF15 level with the risk of developing liver cancer.
- the subjects are subjects who have achieved hepatitis C virus (HCV) sustained negative conversion (SVR), subjects who are on NUC for hepatitis B, and subjects who have developed NAFLD It can be at least one type of subject selected from the group consisting of examiners.
- HCV hepatitis C virus
- SVR sustained negative conversion
- NUC NUC for hepatitis B
- NAFLD NAFLD
- the risk of developing liver cancer in the subject when the GDF15 level of the subject is equal to or higher than a preset cutoff value, the risk of developing liver cancer in the subject is high. It serves as an index, and when it is less than the cutoff value, it can be used as an index that the risk of developing liver cancer in the subject is low.
- the GDF15 level measured in step (1) is the level of GDF15 protein in serum or plasma and/or liver tissue or circulating blood can be the level of the GDF15 transcript of .
- the cutoff value may be set based on statistical analysis or ROC analysis of the GDF15 level.
- the level of GDF15 measured in step (1) may be the level of GDF15 protein in serum.
- the cut-off value may be the median level of the GDF15 protein in the subject for each individual chronic liver disease. It may be determined from the ROC curve for chronic liver disease.
- the cutoff value of the serum GDF15 protein level can be about 1400 pg/mL for hepatitis C patients who have achieved SVR.
- a cut-off value for GDF15 can be about 845 pg/mL for hepatitis B patients on NUC.
- a cutoff value for GDF15 can be about 2000 pg/mL for NAFLD patients.
- the level of GDF15 protein in the serum can be determined by ELISA.
- the cutoff values of AFP and FIB-4 index can be further combined for determination.
- the AFP and FIB-4 index cut-off values are about 5 ng/mL and It may be about 3.25. For subjects who developed NAFLD, it may be about 5 ng/mL and about 2.67, respectively.
- kits for measuring a subject's GDF15 level for use in the methods of the present invention.
- Kits of the invention comprise anti-GDF15 antibodies and/or primer pairs or probes for specifically detecting GDF15 transcripts.
- the present invention provides a diagnostic agent for evaluating a subject's risk of developing liver cancer by the method of the present invention.
- the diagnostic agents of the present invention include anti-GDF15 antibodies and/or primer pairs and probes for specifically detecting GDF15 transcripts.
- the present invention comprises the steps of: (1) measuring the GDF15 level of a subject; (2) Use of GDF15 as a biomarker for evaluating a subject's risk of developing liver cancer, comprising the step of associating the GDF15 level with the risk of developing liver cancer.
- the subject is a subject who has achieved hepatitis C virus (HCV) persistent negative conversion (SVR), It can be at least one type of subject selected from the group consisting of subjects undergoing NUC administration for hepatitis B and subjects who have developed NAFLD.
- HCV hepatitis C virus
- SVR persistent negative conversion
- the present invention provides a method for evaluating the risk of developing liver cancer in a subject according to the present invention, in order to examine the presence or absence of liver cancer in a subject who has been evaluated as having a high risk of developing liver cancer.
- a stratified method for screening a subject for liver cancer is provided, comprising testing at a higher frequency than a subject who has not been tested.
- the presence or absence of the development of liver cancer may be examined based on the findings of ultrasound, contrast-enhanced CT images, MRI and/or liver biopsy tissue.
- Subjects evaluated to have a high risk of developing liver cancer may be examined for the presence or absence of the development of liver cancer based on the findings of ultrasound, contrast-enhanced CT images, and MRI.
- Subjects evaluated to have a low risk of developing liver cancer are not tested for the presence or absence of the development of liver cancer, or the method for evaluating the risk of developing liver cancer in a subject of the present invention.
- Tumor marker tests alone can also be done at regular intervals.
- blood tumor markers include GDF15, AFP ( ⁇ -fetoprotein), AFP-L3 (LCA (lentil lectin) strong binding fraction), and PIVKA-II (protein induced by vitamin K absence or antagonist II).
- GDF15 AFP ( ⁇ -fetoprotein), AFP-L3 (LCA (lentil lectin) strong binding fraction
- PIVKA-II protein induced by vitamin K absence or antagonist II.
- the present invention provides a method for preventing liver cancer, comprising administering a drug for preventing the development of liver cancer to a subject evaluated to have a high risk of developing liver cancer by the liver cancer screening method of the present invention.
- the present invention provides a medicament for preventing the development of liver cancer in a subject evaluated as having a high risk of developing liver cancer by the liver cancer screening method of the present invention.
- subjects can be limited to those with a BMI value of less than 25 kg/m 2 .
- the present invention it is possible to highly accurately evaluate the risk of developing liver cancer based on the GDF15 level of the subject. Accordingly, it is possible to carry out a stratified liver cancer screening method for a subject, which includes examining the presence or absence of liver cancer by tests with different frequencies and/or contents depending on the risk of developing liver cancer. can.
- Pyramid graph showing the distribution of GDF15 levels in stored serum collected at each time point of a derived cohort of hepatitis C patients who achieved SVR.
- the vertical axis indicates serum GDF15 levels (pg/mL).
- the graph on the left shows the distribution of GDF15 levels in serum collected before treatment (Pre Treatment), and the graph in the center shows the distribution of GDF15 levels in serum collected at the end of treatment (End of Treatment),
- the graph on the right shows the distribution of the GDF15 level in serum collected 24 weeks after the achievement of SVR (Post 24 weeks).
- An asterisk (*) indicates a significant difference of p ⁇ 0.0001 by Turkey Kramer test between each of the three graphs in FIG.
- the vertical axis represents the serum GDF15 level (pg/mL), and the horizontal axis represents the relative mRNA level of GDF15 (arbitrary units, AU).
- Pyramid graph showing the distribution of serum GDF15 levels for each fibrosis score group of hepatitis C patients who achieved SVR.
- the vertical axis indicates the serum GDF15 level (pg/mL).
- the horizontal axis is serum GDF15 level (pg/mL), and the vertical axis is age (A), hemoglobin (B), platelet count (C), AST (D), ALT (E), ⁇ GTP (F), eGFR. (G), representing albumin (H), prothrombin time (I), AFP (J) and ALBI score (K).
- Table detailing derived cohort cases of hepatitis C patients who achieved SVR. Graph showing changes in liver cancer incidence over time in a derivation cohort of hepatitis C patients who achieved SVR.
- the vertical axis represents the cumulative incidence of liver cancer, and the horizontal axis represents the observation period (months).
- Pyramid graph showing the distribution of GDF15 levels. The vertical axis indicates serum GDF15 levels (pg/mL). From the left, three time points, Pre Treatment, End Of Treatment, and Post 24 weeks after achieving SVR, groups with and without liver cancer development (Present) shows the distribution of GDF15 levels in the serum of An asterisk (*) indicates that there is a significant difference of p ⁇ 0.005 by Turkey Kramer test between graphs indicating the presence of liver cancer (Present) and the absence (Absent) at the time points in FIG. 6-2.
- the vertical axis represents the serum GDF15 level (pg/mL), and the horizontal axis represents the observation period including 1 year before the onset of liver cancer (-1 year) and the end of observation at the onset of liver cancer.
- the vertical axis represents the cumulative incidence of liver cancer
- the horizontal axis represents the observation period (months).
- the arrows of "GDF15 HIGH” and “GDF15 LOW” point to graphs showing changes over time in the cumulative incidence of liver cancer in the high GDF15 group and the low GDF15 group, respectively.
- (D) represents the area under the curve (AUC) of the ROC curve.
- (E) represents the cut-off value, sensitivity and specificity calculated from the ROC curve of the GDF15, AFP and FIB-4 indices for predicting the development of liver cancer.
- A is a graph showing changes over time in the cumulative incidence of liver cancer in the high AFP group and the low AFP group in hepatitis C patients who achieved SVR.
- B is a graph showing changes over time in the cumulative incidence of liver cancer in the high FIB-4 index group and the low FIB-4 index group in hepatitis C patients who achieved SVR.
- the vertical axis represents the cumulative incidence of liver cancer
- the horizontal axis represents the observation period (months).
- "AFP HIGH”, “AFP LOW”, "FIB4-index HIGH” and "FIB4-index LOW” arrows indicate high AFP group, low AFP group, high FIB-4 index group and low FIB-4 index group, respectively.
- a graph showing changes over time in the cumulative incidence of liver cancer is indicated.
- High risk group (3 points) and intermediate risk group (1-2 points) in patients with hepatitis C who achieved SVR stratified by a scoring system where each high GDF15, AFP and FIB-4 index is 1 point ) and the low-risk group (0 points) graph showing changes over time in the cumulative incidence of liver cancer.
- the vertical axis represents the cumulative incidence of liver cancer, and the horizontal axis represents the observation period (months).
- the "High”, “Middle” and “Low” arrows indicate graphs showing the time course of cumulative liver cancer incidence in the high-risk group, middle-risk group and low-risk group, respectively. Table showing case details of the validation cohort of Hepatitis C patients who achieved SVR.
- A is a graph showing changes over time in the cumulative incidence of liver cancer in the high GDF15 group and the low GDF15 group in hepatitis C patients who achieved SVR.
- B is a graph showing changes over time in the cumulative incidence of liver cancer in the high AFP group and the low AFP group in hepatitis C patients who achieved SVR.
- C is a graph showing changes over time in the cumulative incidence of liver cancer in the high FIB-4 index group and the low FIB-4 index group in hepatitis C patients who achieved SVR.
- the vertical axis represents the cumulative incidence of liver cancer
- the horizontal axis represents the observation period (months).
- "GDF15 HIGH”, “GDF15 LOW”, “AFP HIGH”, “AFP LOW”, “FIB4-index HIGH” and “FIB4-index LOW” arrows indicate high GDF15 group, low GDF15 group and high AFP group, respectively.
- the vertical axis represents the cumulative incidence of liver cancer, and the horizontal axis represents the observation period (weeks).
- the "High”, “Middle” and “Low” arrows indicate graphs showing the time course of cumulative liver cancer incidence in the high-risk group, middle-risk group and low-risk group, respectively.
- the vertical axis represents the cumulative incidence of liver cancer, and the horizontal axis represents the observation period (weeks).
- the "High” arrow represents a graph showing the time course of the cumulative incidence of liver cancer in a group with low AFP and FIB-4 indices but high GDF15 levels.
- the “Low” arrow represents a graph showing the time course of the cumulative incidence of liver cancer in a group with both low AFP and FIB-4 indices and low GDF15 level.
- the vertical axis represents the cumulative incidence of liver cancer, and the horizontal axis represents the observation period (weeks).
- the "High” arrow represents a graph showing the change over time in the cumulative incidence of liver cancer in a group with both high AFP and FIB-4 indices and high GDF15 levels.
- the “Low” arrow represents a graph showing the time course of the cumulative incidence of liver cancer in a group with high AFP and FIB-4 indexes but low GDF15 levels. Scatter plot of pooled sera from criteria-selected hepatitis B cases on NUC.
- Black circles represent non-carcinogenic cases, and white circles represent carcinogenic cases.
- the vertical axis represents the concentration (ng/mL) of GDF15 in the stored serum.
- the vertical axis represents the carcinogenesis rate, and the horizontal axis represents the observation period (days).
- Table of patient demographics across cohorts of hepatitis B cases on NUC grouped by median serum concentration of GDF15 (0.833 ng/mL).
- surface which grouped the patient background of the whole hepatitis B case cohort during NUC administration by the presence or absence of carcinogenesis of liver cancer.
- ROC Receiveiver Operating Characteristic
- Table showing demographics of patients with NAFL or NASH Table showing patient demographics grouped into patients with NAFL and patients with NASH. Graph showing changes in liver cancer incidence over time across patient cohorts with NAFL or NASH. Scatter plot of serum concentration of GDF15 for each case grouped into Brunt Stage types 0-4 for liver fibrosis. Scatter plot examining the correlation between serum concentration of GDF15 and Fib-4 index in patients with NAFL or NASH. Table showing hazard ratios for various attributes, blood markers, Fib-4 index, etc. of patients with NAFL or NASH.
- the vertical axis represents the concentration (ng/mL) of GDF15 in the stored serum. All 9 cases of developed liver cancer were primary hepatocellular carcinoma (HCC). Scatter plot of stored sera from 170 cohorts of Example 3 with extended observation period. Black circles represent non-carcinogenic cases and gray circles represent carcinogenic cases. The vertical axis represents the concentration (ng/mL) of GDF15 in the stored serum. Of the 8 cases of liver cancer that developed, 7 cases were primary hepatocellular carcinoma (HCC), and the 1 case indicated by the arrow was cholangiocellular carcinoma (CCC). Incidence rate of liver cancer in 183 cases of Ogaki Municipal Hospital. Liver cancer incidence in the cohort of Example 3 with extended observation period.
- HCC primary hepatocellular carcinoma
- a total of 353 cases from the Ogaki Municipal Hospital cohort and the cohort of Example 3 with an extended observation period were analyzed for the presence or absence of carcinogenesis 5 years after the stored serum points.
- graph. A total of 353 cases from the Ogaki Municipal Hospital cohort and the cohort of Example 3 with an extended observation period were subjected to ROC (Receiver Operating Characteristic) curve analysis over time regarding the presence or absence of carcinogenesis 7 years after the storage serum point.
- graph. A graph showing changes over time in the incidence of liver cancer with a cutoff value of 2.00 ng/mL for a total of 353 cases in the Ogaki Municipal Hospital cohort and the cohort of Example 3 with an extended observation period.
- GDF15 is a cytokine belonging to the transforming growth factor (TGF) beta superfamily, and is a protein consisting of 308 full-length amino acids. It is highly expressed in the placenta, but weakly expressed in normal tissues other than the placenta. Rapidly up-regulated during inflammation.
- TGF transforming growth factor
- the amino acid sequence of human GDF15 protein and the nucleotide sequence of GDF15 mRNA have been published as NCBI Reference Sequences: NP_004855.2 and NM_004864.4, respectively, and can be isolated by a method known per se.
- the GDF15 level refers to the level of GDF15 protein and/or GDF15 transcript.
- GDF15 protein and GDF15 transcript levels refer to the content of GDF15 protein and GDF15 mRNA, respectively, in a fixed amount of sample.
- the biological species of the GDF15 protein and GDF15 transcript are the same as the biological species of the subject.
- the levels of the GDF15 protein and the GDF15 transcript can be expressed in a manner known to those skilled in the art according to the measurement method described below, for example, it may be expressed as the concentration of the GDF15 protein and the GDF15 transcript, or the concentration of the standard sample. It may be expressed as a relative value based on the measured value.
- the method for measuring GDF15 protein levels uses an immunological technique based on antibodies specific for the GDF15 protein.
- Antibody arrays flow cytometric analysis, radioisotope immunoassay (RIA), ELISA (Engvall E, Methods in Enzymol. 1980;70:419-439.), Western blotting, immunohistochemical assays for measuring GDF15 protein levels.
- Tissue staining enzyme immunoassay (EIA method), fluorescence immunoassay (FIA), immunochromatographic method, immunoturbidimetric method, immunonephelometric method and the like can be used.
- EIA method enzyme immunoassay
- FIA fluorescence immunoassay
- immunochromatographic method immunoturbidimetric method
- immunonephelometric method and the like can be used.
- ELISA is preferred because of its sensitivity and ease of implementation. Details of the ELISA are described in the Examples.
- Methods for measuring GDF15 transcript levels include Northern blotting, RNase protection assay, reverse transcription polymerase chain reaction (RT-PCR) (Weis JH et al., Trends in Genetics 1992;8:263-264.). a quantitative real-time RT-PCR method (HeldCA et al., Genome Research 1996;6:986-994.) and the like can be used. However, the quantitative real-time RT-PCR method is preferred from the viewpoint of sensitivity and ease of implementation. Details of the quantitative real-time RT-PCR method are described in the Examples.
- a subject in the present invention may be any mammal, preferably a mammal with chronic liver disease.
- Mammals include, for example, rodents such as mice, rats, hamsters and guinea pigs, laboratory animals such as rabbits, pets such as dogs and cats, livestock such as cows, pigs, goats, horses and sheep, monkeys, orangutans and Examples include primates such as chimpanzees and humans, and humans are particularly preferred.
- Chronic liver disease herein includes, but is not limited to, viral hepatitis and fatty liver disease.
- Viral hepatitis includes, but is not limited to, hepatitis C and hepatitis B.
- Fatty liver disease includes, but is not limited to, non-alcoholic fatty liver disease (NAFLD) and secondary fatty liver.
- NAFLD includes, but is not limited to, nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH).
- Subjects in the present invention include patients with chronic liver disease who need to be evaluated for the risk of developing liver cancer.
- Subjects of the present invention include, but are not limited to, post-SVR subjects in hepatitis C, subjects under NUC administration in hepatitis B, subjects suffering from NASH.
- Hepatitis C Guidance 2019 Update American Association for the Study of Liver Diseases- Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 2020;71:686-721. 2020;73:1170-1218.).
- non-alcoholic fatty liver disease NAFLD/NASH clinical practice guidelines 2020 Edited by the Society of Diseases and the Japanese Society of Hepatology, revised 2nd edition, published in November 2020, Nankodo (https://www.jsge.or.jp/guideline/guideline/pdf/nafldnash2020.pdf), English version (Tokushige 2021;51:1013-1025. and Tokushige, K. et al. Journal of Gastroenterology 2021;56: 951-963.). As defined by the house.
- tests to determine the presence or absence of liver cancer development from chronic viral hepatitis, fatty liver disease and other liver diseases include liver cancer clinical practice guidelines (edited by the Japan Society of Hepatology, 2017 edition, supra). according to authoritative liver cancer expert definitions.
- determining the risk of developing liver cancer includes performing evaluation and testing in light of certain criteria. Specifically, subjects who have not developed liver cancer after achieving SVR for HCV, subjects who have not developed liver cancer during treatment with NUC administration for HBV, and NAFL, NASH and other fatty liver diseases
- a risk of developing liver cancer in the future in a subject with chronic liver disease but not developing liver cancer means to determine whether or not there is, and includes determining whether or not there is a risk of developing liver cancer, and determining the level of the risk of developing liver cancer.
- subjects are stratified according to the degree of risk of developing liver cancer, and resources for liver cancer screening tests are allocated to subjects with a higher risk of developing liver cancer than subjects with a low risk of developing liver cancer.
- One purpose is to provide a gradient distribution to the subject.
- the risk of developing liver cancer is associated with the subject's GDF15 level. Specifically, whether the subject's GDF15 level is higher or lower than a preset cutoff value serves as an indicator of whether the subject's risk of developing liver cancer is high or low.
- the cut-off value in the present invention is determined by preparing a database that traces the individual GDF15 levels and the presence or absence of liver cancer development for evaluation populations of chronic liver disease patients, and the GDF15 levels of liver cancer patients and liver cancer non-developers. is preset based on statistical analysis or ROC analysis of the data.
- the cut-off value is determined by statistical analysis, for example, the median value, arithmetic mean or other mean value of the GDF15 level data of the evaluation group can be used.
- the cutoff value based on ROC analysis is 1.0 on the vertical axis (sensitivity or true positivity) of the ROC curve graph, and 1.0 on the horizontal axis (1- Specificity) can be the GDF15 level of the point on the ROC curve that has the smallest distance from the point where the specificity) is 0.0, or derived from the Youden index of the ROC curve (Cancer 1950;3:32-35.) can be a cut-off value
- the evaluation population database of chronic liver disease patients may be used for setting a cutoff value in the method of evaluating the risk of developing liver cancer in a subject of the present invention without any changes.
- a new chronic liver disease patient including the subject of the present invention, is incorporated into the evaluation population, and the database of the evaluation population of chronic liver disease patients is updated as appropriate, while the liver cancer of the subject of the present invention It may be used for setting a cut-off value in a method for evaluating onset risk.
- the cut-off value for predicting the onset of liver cancer determined by the ROC curve in the observational study of the inventors of the present invention is was included in the numerical range of 90% or more and 110% or less of the median GDF15 level of Therefore, the median value may be used as the cutoff value.
- the cutoff value of the serum GDF15 protein level can be about 1400 pg/mL for hepatitis C patients who have achieved SVR. .
- a cut-off value for GDF15 can be about 845 pg/mL for hepatitis B patients on NUC.
- a cutoff value for GDF15 can be about 2000 pg/mL for NAFLD patients.
- the cutoff values of AFP and FIB-4 index can be further combined for determination.
- the AFP and FIB-4 index cutoff values may be about 5 ng/mL and about 3.25, respectively, for hepatitis C patients who have achieved SVR.
- the method for evaluating the risk of developing liver cancer in a subject of the present invention will be described separately as a method based on the GDF15 protein level of the subject and a method based on the GDF15 transcript level of the subject. .
- a method for evaluating the risk of developing liver cancer in a subject with chronic liver disease based on the GDF15 protein level A method for evaluating the onset risk, (1) measuring the subject's GDF15 protein level; (2) A method is provided, comprising the step of associating the GDF15 protein level with the risk of developing liver cancer.
- the subject's GDF15 protein level is measured using the subject's serum or plasma sample.
- Subject's plasma and serum can be prepared by a method known per se from a peripheral blood sample collected from the subject. These may be appropriately diluted using a known buffer solution or the like depending on the means for measuring the GDF15 protein level. ) may be diluted 75- to 100-fold or more using an attached dilution buffer or the like. If it takes time from blood collection to measurement, it is possible to measure plasma and/or serum that has been cryopreserved.
- the level of GDF15 protein in step (1) can be measured by an immunological method using an antibody that specifically recognizes GDF15 protein (ie, GDF15-specific antibody).
- Immunological methods include antibody array, flow cytometry analysis, radioisotope immunoassay (RIA method), ELISA (Methods in Enzymol. 70: 419-439 (1980)), Western blotting, immunohistochemical staining, enzyme Immunoassay (EIA method), fluorescence immunoassay (FIA), immunochromatographic method, immunoturbidimetric method, immunonephelometric method and the like can be mentioned, but ELISA is preferable from the viewpoint of sensitivity and ease of implementation.
- Specific recognition of antigen X by an antibody means that the affinity of the antibody for antigen X in the antigen-antibody reaction is stronger than the affinity for antigens other than antigen X.
- an antibody that specifically recognizes antigen X may be abbreviated as “anti-X antibody” or "X-specific antibody”.
- the GDF15-specific antibody may be either a polyclonal antibody, a monoclonal antibody, or a binding fragment thereof.
- the antibody may be directly or indirectly labeled with a labeling substance.
- labeling substances include fluorescent substances (eg, FITC, rhodamine), radioactive substances (eg, 32 P, 35 S, 14 C, 3 H), enzymes (eg, alkaline phosphatase, peroxidase), colored particles (eg, metal colloids). particles, colored latex), biotin, and the like.
- the antibody can be used in a soluble state that is not bound to anything else, it may be bound to a solid phase.
- solid phase examples include plates (e.g., microwell plates), tubes, beads (e.g., plastic beads, magnetic beads), chromatography carriers (e.g., water-absorbent substrates such as nitrocellulose membranes, Sepharose), membranes (eg, nitrocellulose membrane, PVDF membrane), gel (eg, polyacrylamide gel), metal membrane (eg, gold membrane), and the like.
- plates, beads, chromatographic carriers and membranes are preferably used, and plates are most preferably used because they are easy to handle.
- binding to the solid phase may be direct binding to the solid phase, or indirect binding to the solid phase using a substance known per se.
- a phosphate buffer solution such as bovine serum albumin (BSA) or bovine milk protein is brought into contact with the solid phase, and the solid phase surface portion not coated with the antibody is removed. Blocking with the aforementioned BSA, cow milk protein or the like is generally performed.
- the contact of the GDF15-specific antibody with plasma or serum derived from the subject is not particularly limited in terms of mode, order, specific method, etc., as long as these antibodies can interact with GDF15 in plasma or serum.
- Contacting can be achieved, for example, by adding plasma or serum to a plate on which antibodies are immobilized.
- proteins in plasma or serum may be separated by means such as SDS-PAGE, transferred to a membrane, fixed, and then brought into contact with an antibody.
- the time for which such contact is maintained is not particularly limited as long as it is sufficient for the antibody and GDF15 contained in plasma or serum derived from the subject to bind and form a complex, but usually , several seconds to ten hours.
- the temperature conditions for the contact are usually 4°C to 50°C, preferably 4°C to 37°C, most preferably room temperature of about 15°C to 30°C.
- the pH condition for the reaction is preferably 5.0 to 9.0, more preferably a neutral range of 6.0 to 8.0.
- the commercially available GDF15 protein is used, and the ELISA results of the dilution series are quantified by fluorescence, color development, or other reaction to easily determine the absolute value of the concentration of the GDF15 protein, for example, pg /mL.
- step (2) the level of GDF15 protein in plasma and/or serum of the subject measured in step (1) is associated with the risk of developing liver cancer.
- Associating the level of GDF15 protein in plasma and/or serum with the risk of developing liver cancer refers to determining whether the subject's data suggests (or indicates) the risk of developing liver cancer. .
- the association between the subject's data and the risk of developing liver cancer is usually performed by comparing the subject's data with the data of patients with chronic liver disease other than the subject.
- the group in which the level of GDF15 protein is higher than the preset cutoff value (high GDF15 group) has a higher risk of developing liver cancer than the group lower than the preset cutoff value (low GDF15 group). It became clear. This makes it possible to evaluate the risk of developing liver cancer in a subject.
- the method for evaluating the risk of developing liver cancer of the present invention may include the step of determining the risk of developing liver cancer by a cutoff value of the GDF15 protein level, wherein the GDF15 protein level of the subject is equal to or higher than the cutoff value. If so, the subject's risk of developing liver cancer is high, and if the subject's GDF15 protein level is less than the cutoff value, the subject's risk of developing liver cancer is low. Further, the cut-off value can be the median GDF15 protein level of the population of subjects.
- the adnominal "about” that modifies a numerical value means a numerical range of 90% or more and 110% or less of the numerical value.
- “1400 pg/mL” refers to a numerical range of 1260 pg/mL or more and 1540 pg/mL or less.
- the cutoff value determined as the median serum GDF15 protein level in hepatitis C patients who have achieved SVR may be about 1400 pg/mL.
- the cut-off value in hepatitis C patients who achieved SVR determined as the serum concentration of GDF15 at which the Youden index was maximized by the ROC curve, was 1448 pg/mL, determined as the median value. This is because it falls within a numerical range of 90% or more and 110% or less of the cutoff value of 1400 pg/mL.
- the cutoff values of AFP and/or FIB-4 index can be further combined for determination.
- AFP and FIB-4 index can be used in combination to determine.
- AFP can be used in combination with GDF15 for determination. This is because a method for stratifying the risk of developing liver cancer in subjects who have achieved SVR after DAA treatment using AFP and FIB-4 index as markers has been known.
- Prior art known to those skilled in the art has used cut-off values for the AFP and FIB-4 indices of 5 ng/mL and 3.25, respectively.
- a method for evaluating the risk of developing liver cancer in a subject with chronic liver disease based on the GDF15 transcript level A method for evaluating the risk of developing liver cancer, (1) measuring the subject's GDF15 transcript level; (2) A method is provided, comprising the step of associating the GDF15 transcript level with the risk of developing liver cancer.
- the subject's GDF15 transcript level is measured using the subject's biological tissue, serum or plasma sample.
- the biological tissue includes, but is not limited to, percutaneous biopsy (needle biopsy), endoscopic biopsy, and surgical biopsy. can be obtained.
- the biological tissue is preferably liver tissue. Circulating GDF15 transcripts or portions thereof in serum or plasma samples can also be measured.
- RNA can be isolated from a biological sample according to routine methods. General methods for extracting RNA are well known in the art and are described in molecular Disclosed in Biology Laboratory Protocols. Specifically, RNA isolation can be performed using commercially available purification kits such as RNeasy columns (Qiagen, Hulsterweg, Germany) according to the manufacturer's instructions.
- RNA for example, reverse transcription polymerase chain reaction (RT-PCR), quantitative real-time RT-qPCR, etc.
- RT-PCR reverse transcription polymerase chain reaction
- Complementary DNA is prepared from RNA using a GDF15-specific primer by reverse transcription reaction, and using the complementary DNA as a template, a reaction solution containing a GDF15-specific PCR primer pair and a fluorescence-labeled probe is amplified with a real-time PCR device, and fluorescence is quantified. can do.
- the relative value of the measured GDF15 transcript in RNA from the subject sample to be measured relative to the measured GDF15 transcript in control RNA at the same concentration can be quantified.
- Arbitrary Units (AU) can be used in the case of the relative value of the measured value of the GDF15 transcript.
- the primer pair and probe for specifically detecting the GDF15 transcript used in step (1) can be synthesized based on the nucleotide sequence of human GDF15 mRNA published as NCBI Reference Sequence: NM_004864.4.
- Base lengths of primers and probes are not particularly limited.
- the primer comprises a forward primer containing one of a partial nucleotide sequence of the nucleotide sequence of the human GDF15 mRNA and a partial nucleotide sequence of the nucleotide sequence complementary to the nucleotide sequence of the human GDF15 mRNA, and the other is a reverse primer.
- the base length of each primer can be 10 to 50 nucleotides, preferably 15 to 30 nucleotides.
- the probe includes a portion of a nucleotide sequence complementary to the nucleotide sequence of the human GDF15 mRNA, and the base length of the probe ranges from 10 nucleotides to the entire length of the nucleotide sequence complementary to the nucleotide sequence of the human GDF15 mRNA, preferably. can be 20-150 nucleotides.
- Primer pairs and probes for specifically detecting GDF15 transcripts used in step (1) may be natural nucleic acids such as RNA and DNA, and may optionally combine natural nucleic acids with chemically modified nucleic acids or pseudo-nucleic acids.
- Examples of chemically modified nucleic acids and pseudo-nucleic acids include PNA (Peptide Nucleic Acid), LNA (Locked Nucleic Acid; registered trademark), methylphosphonate-type DNA, phosphorothioate-type DNA, 2'-O-methyl-type RNA, and the like.
- primers and probes may be labeled with fluorescent substances and/or quencher substances, or radioactive isotopes (e.g., 32 P, 33 P, 35 S), biotin or (strept)avidin, or magnetic beads. It may be labeled or modified with a modifier. Labeling substances are not limited, and commercially available ones can be used. For example, fluorescent substances such as FITC, Texas, Cy3, Cy5, Cy7, Cyanine3, Cyanine5, Cyanine7, FAM, HEX, VIC, fluorescamine and its derivatives, and rhodamine and its derivatives can be used. AMRA, DABCYL, BHQ-1, BHQ-2, or BHQ-3 can be used as quencher substances.
- the labeling positions of the labeling substances in the primers and probes may be appropriately determined according to the properties of the modifying substance and the purpose of use. In general, the 5' or 3' end is often modified. Also, one primer and one probe molecule may be labeled with one or more labeling substances.
- the design of the nucleotide sequences of primers and probes and the selection of labeling substances are known, and molecular biology such as Sambrook, J and Russell, DW, Molecular Cloning: A Laboratory Manual (3rd ed., Cold Spring Harbor Laboratory Press, 2001). are disclosed in the experimental protocol book.
- step (2) the level of the subject's GDF15 transcript measured in step (1) is associated with the risk of developing liver cancer.
- Associating the level of the GDF15 transcript with the risk of developing liver cancer means determining whether or not the subject's data suggests (or indicates) the risk of developing liver cancer.
- the association between the subject's data and the risk of developing liver cancer is usually performed by comparing the subject's data with the data of patients with chronic liver disease other than the subject.
- the level of the GDF15 transcript is higher than the preset cutoff value (high GDF15 group) group lower than the preset cutoff value (low GDF15 group) than the risk of developing liver cancer revealed to be high. This makes it possible to evaluate the risk of developing liver cancer in a subject.
- the method for assessing the risk of developing liver cancer of the present invention may include the step of determining the risk of developing liver cancer by a cutoff value of the GDF15 transcript level, wherein the GDF15 transcript level of the subject is the cutoff value If the GDF15 transcript level of the subject is less than the cutoff value, the subject's risk of developing liver cancer is determined to be low. Further, the cutoff value can be the median GDF15 transcript level of the population of subjects.
- the method for assessing the risk of developing liver cancer of the present invention may include the step of determining the risk of developing liver cancer by a cutoff value of the GDF15 transcript level, wherein the GDF15 transcript level of the subject is the cutoff value If the GDF15 transcript level is less than the cutoff value, the risk of developing liver cancer in the subject is high. Further, the cutoff value can be the median GDF15 transcript level of the population of subjects.
- the cutoff values of AFP and FIB-4 index can be further combined for determination. This is because a method for stratifying the risk of developing liver cancer in subjects who have achieved SVR after DAA treatment using AFP and FIB-4 index as markers has been known. Prior art known to those skilled in the art has used cut-off values for the AFP and FIB-4 indices of 5 ng/mL and 3.25, respectively.
- kits for Measuring GDF15 Levels in Subjects for Use in the Methods of the Present Invention provides kits for measuring GDF15 levels in subjects for use in the methods of the present invention.
- the kit of the present invention comprises anti-GDF15-specific antibodies and/or primer pairs and probes for specifically detecting GDF15 transcripts.
- the anti-GDF15-specific antibody contained in the kit of the present invention is described in "1.
- the primer pair and probe for specifically detecting the GDF15 transcript contained in the kit of the present invention are described in "2. Based on the GDF15 transcript level in subjects suffering from chronic liver disease. Methods for assessing a subject's risk of developing liver cancer" section.
- the present invention uses the method of the present invention to evaluate the risk of developing liver cancer in a subject with chronic liver disease provide diagnostics for
- the diagnostic agent of the present invention includes anti-GDF15 antibodies and/or primer pairs and/or probes for specifically detecting GDF15 transcripts.
- the risk of developing liver cancer of the subject is evaluated based on the GDF15 protein level of the subject suffering from chronic liver disease.
- method for For the primer pair and / or probe for specifically detecting the GDF15 transcript contained in the diagnostic agent of the present invention the "2. GDF15 transcript level of subjects suffering from chronic liver disease Method for assessing the risk of developing liver cancer in said subject based on the method" section.
- GDF15 as a biomarker for assessing the risk of developing liver cancer in a subject
- the present invention provides the use of GDF15 as a biomarker for assessing the risk of developing liver cancer in a subject.
- the steps involved in the use of GDF15 of the present invention are described in "1. Method for assessing the risk of developing liver cancer in a subject with chronic liver disease based on the GDF15 protein level. and "2. Methods for assessing the risk of developing liver cancer in a subject with chronic liver disease based on the GDF15 transcript level in said subject" sections.
- Example 1 Liver cancer development risk assessment in subjects who achieved hepatitis C virus (HCV) persistent negative conversion (SVR).
- HCV hepatitis C virus
- SVR persistent negative conversion
- Antiviral therapy and SVR DAA treatment was carried out with a protocol of asunaprevir and daclatasvir for 24 weeks, sofosbuvir and ledipasvir for 12 weeks, ombitasvir and paritaprevir plus ritonavir for 12 weeks, sofosbuvir and ribavirin for 12 weeks, elbasvir and grazoprevir for 12 weeks.
- SVR refers to undetectable HCV RNA levels 24 weeks after the end of treatment. All cases were treated in accordance with the Japanese Society of Hepatology guidelines for the treatment of chronic HCV infection.
- the follow-up start date is the date DAA treatment ended. Endpoints were the date of onset of liver cancer or the date of final follow-up liver cancer surveillance imaging. The overall survival endpoint was the date of death from all causes or the date of last follow-up.
- Sera test Sera from enrolled cases were stored in a -80°C freezer at Osaka University at the time points determined by the prospective study protocol.
- Serum GDF15 concentrations were determined using a human enzyme-linked immunosorbent assay (ELISA) kit (#DGD150, R&D systems, Minneapolis, Minn.) according to the manufacturer's protocol. Absorbance was determined on a Varioscan LUX (Thermo Scientific, Waltham, Mass.).
- the cases were divided into two groups with a median pretreatment serum GDF15 level of 1400 pg/mL. As the details of the cases of the high GDF15 group and the low GDF15 group are shown in FIG. Blood glucose, HbA1c, AFP, FIB-4 index and ALBI scores were high, HCV RNA levels, hemoglobin, eGFR and albumin were low. A correlation between the serum GDF15 level and the fibrosis score was observed (Fig. 4-1). A correlation between serum GDF15 levels and FIB-4 index values was observed (Fig. 4-2).
- the serum GDF15 level is different from old age (Figure 4-3A), high AST ( Figure 4-3D), low eGFR (Figure 4-3G), low albumin (Figure 4-3H) and high A correlation was also observed with the ALBI score (FIGS. 4-3K).
- liver cancer In the derivation cohort, 49 cases developed liver cancer after DAA treatment within the observation period of the present invention. The details are shown in FIG. The incidence of liver cancer in the derivation cohort was 1.59% at 1 year, 2.85% at 2 years, and 5.02% at 3 years (Fig. 6-1). Patients with post-treatment liver cancer developed serum GDF15 levels at any of the three time points: Pre Treatment, End Of Treatment, and 24 weeks after achieving SVR (Post 24 weeks). It was higher than non-symptomatic cases (Fig. 6-2). The GDF15 level at the onset of liver cancer showed no significant change compared to the GDF15 level one year before the onset of liver cancer (Fig. 6-3). This suggests that serum GDF15 levels may reflect the severity of liver disease at that time in each case, unlike tumor markers such as AFP and PIVKA2.
- the 1, 2 and 3-year cumulative liver cancer incidence rates were 2.80%, 4.44% and 8.31%, respectively, in the high GDF15 group, and 0.47%, 1.0%, respectively, in the low GDF15 group. 12% and 1.93%.
- the 1-, 2-, and 3-year cumulative liver cancer incidence rates were significantly lower in the low GDF15 group than in the high GDF15 group (Fig. 6-4).
- Serum GDF15 level may be a novel biomarker for predicting liver cancer development after DAA treatment.
- pretreatment variables associated with liver cancer development were analyzed by the Cox Hazard model. Cases with a FIB-4 index greater than 3.25 (>3.25) are based on past findings (Gastroenterology 2017; 153: 996-1005. e1001. and Hepatology 2007; 46: 32-36.) A case of advanced hepatic fibrosis was considered. Other variables were assigned to two groups based on median or historical findings (Clin Gastroenterol Hepatol 2014;12:1186-1195.).
- AFP as a tumor marker
- GDF15 level As a tumor marker
- FIB-4 index as fibrosis progression calculated by age
- AST ALT and platelets
- ALBI score calculated by albumin and bilirubin parameters.
- a multivariate Cox regression model was selected. Among these parameters, AFP (J Med Virol 2020;92:3507-3515. and J Hepatol 2017;67:933-939.), FIB-4 index (Gastroenterology 2017;153:996-1005.e1001., J Med Virol 2020;92:3507-3515. and J Hepatol 2017;68:25-32.) and ALBI score (Dig Liver Dis 2019;51:681-688.) are risk factors for liver cancer after HCV elimination is known.
- High GDF15 (HR 2.52 95% CI 1.17-6.09), high AFP (HR 2.26 95% CI 1.16-4.69) and high FIB-4 index (HR 2.40 95% CI 1.18-5.24) independently increased the risk of developing HCC. (Fig. 7). No significant difference was observed in the predictive power of liver cancer development among AFP, FIB-4 index and GDF15 (Fig. 8). The cumulative liver cancer incidence rate was 8-9% over 3 years in the high AFP group or high FIB-4 index group, and 2-3% over 3 years in the low AFP group or low FIB-4 index group (Fig. 9A and B).
- the cutoff values of the GDF15, AFP and FIB-4 indices for predicting the development of liver cancer were determined by the ROC curve on the Youden index (Cancer 1950;3:32-35.)
- the cutoff values of the serum GDF15, AFP and FIB-4 indices were The values were 1448 pg/mL, 6.020 ng/mL and 3.025, respectively (Fig. 8E). These cut-off values were similar to pretreatment median serum GDF15 levels of 1400 pg/mL, 5 ng/mL and 3.25 (Fig. 7).
- the total score for each case was calculated, with 1 point for each high GDF15, AFP and FIB-4 index.
- a score of 0 was defined as a low risk group
- a score of 1 or 2 was defined as an intermediate risk group
- a score of 3 was defined as a high risk group.
- the cumulative risk of developing liver cancer for 1, 2 and 3 years is 0%, 0.40% and 0.40% for the low risk group, and 1.18%, 1.89% and 4.44% for the intermediate risk group, respectively. , 4.95%, 8.26%, and 13.2% in the high-risk group (Fig. 10).
- a scoring system using GDF15 levels, AFP and FIB-4 index can stratify the risk of developing liver cancer in the validation cohort.
- the risk of developing liver cancer was stratified by a scoring system using GDF15 levels, AFP and FIB-4 index.
- the scoring system was validated using a validation cohort of 751 cases for which only pre-DAA serum was available. In the validation cohort, 39 cases developed liver cancer after DAA treatment during the observation period (Fig. 11).
- the cumulative incidence of liver cancer in the low GDF15 group, low AFP group and low FIB-4 index group was significantly lower than in the high GDF15 group, high AFP group and high FIB-4 index group, respectively (FIGS. 13A-C).
- the total score for each case was calculated, with 1 point for each high AFP and FIB-4 index of known markers.
- a score of 0 was defined as a low risk group
- a score of 1 was defined as a middle risk group
- a score of 2 was defined as a high risk group.
- the degree of stratification of the Kaplan-Meier curve for each risk group was rough, and even in the low-risk group, the incidence of liver cancer comparable to that in the intermediate-risk group was observed.
- the low-risk group in the known marker AFP and FIB-4 index only scoring system was divided into a group with both low AFP and FIB-4 indices but high GDF15 levels and a group with both low AFP and FIB-4 indices. value, and the GDF15 level is also low value group, as shown in Figure 15-2, both AFP and FIB-4 index is low, and GDF15 level is also low in the group of liver cancer The onset rate became 0.
- both AFP and FIB-4 indexes are low, but the incidence of liver cancer is about 7% in a group with high GDF15 level, and stratification by low AFP and low FIB-4 index alone is not enough. It was confirmed that the risk of developing liver cancer after DAA treatment is not sufficiently low.
- the examples of the present invention are retrospective studies using stored serum, and bias related to the availability of serum cannot be denied. To dispel this concern, we compared the derivation cohort and the validation cohort and showed at least no significant difference in liver cancer incidence. In addition, Myojin, Y. et al. (Aliment Pharmacol Ther. 2022; 55: 422-433) randomly distributed the cases of the derivation cohort and validation cohort of this example to 3: 2. Derivation cohort (964 cases) and validation cohort (642 cases), the cut-off values determined by the ROC curve of the serum GDF15, AFP and FIB-4 indices as the maximum Youden index were 1350 pg/mL, 5 ng/mL and 3.5 pg/mL, respectively. was 25. These values were similar to the median serum GDF15 levels before treatment in this example.
- Example 2 Evaluation of the risk of developing liver cancer in subjects who have not developed liver cancer during treatment with NUC administration for hepatitis B virus (HBV)A.
- Materials and Methods (1) Case Population Subject to Investigation Subjects of the investigation in this example are nucleic acid analog (NUC)-administered cases with preserved serum whose long-term course can be investigated.
- NUC nucleic acid analog
- the criteria for selecting stored serum are that there is a history of NUC administration for 8 months or more at stored serum points (if there are multiple stored serum points, the oldest serum point among applicable serum points), and stored serum points and serum HBV DNA less than 3.0 logIU/ml.
- patients with a history of liver cancer at the time of serum points and patients with liver diseases other than hepatitis B are excluded.
- NUC nucleic acid analogue
- Serum GDF15 levels were higher in patients who developed liver cancer during treatment with NUC administration for HBV than in patients who did not develop liver cancer.
- a scatter plot of the serum concentration of GDF15 in the cases under treatment with NUC administration, a graph showing the patient background, and a graph showing the time course of the incidence of liver cancer in the entire cohort of this time are shown in FIGS. 16, 17 and 18, respectively.
- the cohort-wide median and 25%-75% interval of serum concentrations of GDF were 0.833 ng/mL and 0.555-1.206 ng/mL.
- FIG. 19 is a table in which patient backgrounds are grouped by median serum concentration of GDF15 (0.833 ng/mL).
- FIG. 20 is a table in which patient backgrounds are grouped according to the presence or absence of onset of liver cancer.
- Figures 21 and 22 are graphs of the results of ROC (Receiver Operating Characteristic) curve analysis over time regarding the presence or absence of carcinogenesis at 5 and 10 years from the stored serum points for GDF15, Fib4, AFP and Plt, respectively. is.
- the vertical axis of each graph represents sensitivity or true positivity
- the horizontal axis represents false positivity (1-specificity)
- AUC represents the area under the ROC curve of each graph (Area under the curve).
- FIG. 23 shows a graph showing changes over time in the incidence of liver cancer using a cutoff value (0.845 ng/mL) determined from the ROC curve as the maximum Youden index.
- FIG. 24 shows the results of univariate/multivariate analysis of factors contributing to carcinogenesis by cox proportional hazards model.
- Figure 25 shows that the results of multivariate analysis were good, and each score was given to cases with cutoff values of 5 ng / mL and 0.845 ng / mL or more for each of the two markers, AFP and GDF15.
- the cases are grouped and plotted to represent a graph showing the time course of the incidence of liver cancer. Therefore, stratification by a scoring system using the novel biomarker GDF15 alone or GDF15 in combination with the known marker AFP was shown to be useful for predicting the development of liver cancer in HBV patients undergoing treatment with NUC administration.
- the serum concentration marker of GDF15 is useful for predicting hepatic carcinogenesis even in subjects who have not developed liver cancer during treatment with NUC administration for hepatitis B virus (HBV). .
- Example 3 Liver cancer development risk assessment for subjects with NAFL or NASH but not liver cancer A.
- Materials and methods (1) Case population to be investigated This is a case with stored serum. However, patients with a history of liver cancer at the time of serum points and patients with liver diseases other than NAFLD are excluded.
- NAFL non-alcoholic fatty liver
- NASH non-alcoholic steatohepatitis
- NAFLD/NASH Clinical Guidelines 2020 (edited by the Japanese Society of Gastroenterology and the Japan Society of Hepatology, revised 2nd edition) , published in November 2020, Nankodo (https://www.jsge.or.jp/guideline/guideline/pdf/nafldnash2020.pdf)), English version (Tokushige, K. et al. HepatologyResearch.2021;51: 1013-1025. and Tokushige, K. et al. Journal of Gastroenterology 2021;56: 951-963.), which were treated according to guidelines available at the time.
- FIG. 26 is a scatter plot of serum concentrations of GDF15 in patients with NAFL or NASH.
- black circles represent non-liver cancer cases, and white circles represent liver cancer-developed cases.
- Five of the six cases of liver cancer that developed were primary hepatocellular carcinoma (HCC), and the one indicated by the arrow was cholangiocellular carcinoma (CCC).
- Figure 27 is a table showing patient demographics of patients with NAFL or NASH.
- Figure 28 is a table showing patient demographics grouped into patients with NAFL and patients with NASH. As shown in Figure 28, the cohort-wide median and 25%-75% interval of serum concentrations of GDF in patients with NAFL were 1.07 ng/mL and 0.69-1.49 ng/mL.
- Figure 29 is a graph showing the time course of liver cancer incidence across patient cohorts with AFL or NASH.
- Fig. 30 is a scatter diagram of the serum concentration of GDF15 for each case grouped into types 0 to 4 of Brunt Stage.
- the Jonckheere-Terpstra trend test was used to verify the tendency of the serum concentration of GDF15 to increase in each group as the stage progressed from Brunt Stage type 0 to type 4, the significant difference P was 0.003. Therefore, from FIG. 30, a significant correlation was observed between the serum concentration of GDF15 and fibrosis.
- FIG. 31 is a scatter plot examining the correlation between the serum concentration of GDF15 and the Fib-4 index in patients with NAFL or NASH.
- the significant difference P was less than 0.0001 and the coefficient of determination R2 was 0.245, indicating a significant correlation.
- FIG. 32 is a table showing the hazard ratios of various attributes, blood markers, Fib-4 index, etc. of patients suffering from NAFL or NASH.
- the P-value for GDF15 is less than 0.0001, significantly lower than any other attribute, blood marker, Fib-4 index, etc.
- FIG. 33 is a graph of the results of ROC (Receiver Operating Characteristic) curve analysis over time regarding the presence or absence of carcinogenesis 5 years after the storage serum point for each of the GDF15 and Fib-4 indexes.
- the vertical axis of each graph represents sensitivity or true positivity
- the horizontal axis represents false positivity (1-specificity)
- AUC represents the area under the ROC curve of each graph (Area under the curve).
- 34-1 and 34-2 represent graphs showing changes over time in liver cancer incidence with cutoff values of 2.00 ng/mL and 1.35 ng/mL, respectively.
- 2.00 ng/mL is the cut-off value determined from the ROC curve of carcinogenesis within 5 years in a cohort of NAFL or NASH patients assuming that the Youden index is the maximum value.
- 1.35 ng/mL is the cutoff value determined from the ROC curve from the derivation cohort of hepatitis C patients who achieved SVR in Example 1 assuming the Youden index to be the maximum value. It was shown that stratification with a cutoff value of 2.00 ng/mL greatly contributes to the prediction of liver cancer incidence in NAFL and NASH.
- the serum concentration marker of GDF15 is useful for predicting hepatic carcinogenesis even for subjects suffering from NAFLD including NAFL and NASH.
- Example 4 Study with Additional Cohort of Ogaki Municipal Hospital 183 cases of Ogaki Municipal Hospital were added and further studied.
- Case population to be investigated This is a case with stored serum. However, patients with a history of liver cancer at the time of serum points and patients with liver diseases other than NAFLD are excluded.
- Results Figures 35-1 and 35-2 show patient backgrounds of Ogaki Municipal Hospital and Example 3 cohort with extended observation period, respectively.
- Fig. 36-1 is a scatter diagram of serum concentrations of GDF15 in patients suffering from NAFLD at Ogaki Municipal Hospital.
- black circles represent non-liver cancer cases
- gray circles represent liver cancer-developed cases. All 9 cases of developed liver cancer were primary hepatocellular carcinoma (HCC).
- FIG. 36-2 is a scatter plot of serum concentrations of GDF15 in patients with NAFLD in the cohort of Example 3 with extended observation period.
- black circles represent non-liver cancer cases
- gray circles represent liver cancer-developed cases.
- 7 cases were primary hepatocellular carcinoma (HCC)
- the 1 case indicated by the arrow was cholangiocellular carcinoma (CCC).
- HCC primary hepatocellular carcinoma
- Figures 37-1 and 37-2 show changes in liver cancer incidence over time in the Ogaki Municipal Hospital cohort and the cohort of Example 3 with an extended observation period, respectively.
- Figures 38-1, 38-2 and 38-3 show carcinogenesis at 5 years and 7 years from the storage serum point, respectively, in the Ogaki Municipal Hospital cohort and the cohort of Example 3 with an extended observation period. It is a graph of the results of ROC (Receiver Operating Characteristic) curve analysis over time for the presence or absence of The vertical axis of each graph represents sensitivity or true positivity, the horizontal axis represents false positivity (1-specificity), and AUC represents the area under the ROC curve of each graph (Area under the curve).
- ROC Receiveiver Operating Characteristic
- FIG. 10 is a graph showing changes over time in the incidence of liver cancer in patients with liver cancer.
- 2.00 ng/mL is the cut-off value determined as the maximum Youden index from the ROC curve of a cohort of NAFLD patients observed for 5 years.
- 1.74 ng/mL is the cut-off value determined as the maximum Youden index from the ROC curve of a cohort of NAFLD patients observed for 7 years. It was shown that stratification with cutoff values of 2.00 ng/mL and 1.74 ng/mL greatly contributes to the prediction of liver cancer incidence in NAFLD.
- the present invention it is possible to more accurately evaluate a subject's risk of developing liver cancer based on the GDF15 level.
- subjects are stratified according to the evaluated degree of risk of developing liver cancer, and subjects with a high risk of developing liver cancer undergo a liver cancer screening test at a higher frequency than subjects with a low risk of developing liver cancer. can be graded as follows: Therefore, it is possible to reduce both the examination burden on individual subjects and the medical economic loss for society as a whole.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Description
C型肝炎に対する新規治療薬である直接型抗ウイルス薬(direct acting antivirals、以下、「DAAs」という。)の登場により多くの症例でC型肝炎ウイルス(HCV)が排除されるようになった。C型肝炎ウイルス排除後、正確には、持続陰性化(sustained virological response、以下、「SVR」という。)達成後も肝発癌、正確には、肝癌発症のリスクがある(非特許文献5)ので、C型肝炎の多くの症例で治療終了後に定期的な画像検査や血液検査を行っている。しかし、近年DAAs治療の普及によりSVRを達成した症例が増大しており、全てのSVR達成症例に一律の定期検査を行うのは医療経済上問題がある。そこで肝発癌リスクを層別化して、肝発癌リスクの高い集団を重点的に検査する必要がある。血液検査で腫瘍マーカーとして、AFP(αフェトプロテイン)、血小板や年齢から計算されるFIB-4インデックス(Fib-4、FIB4又はFib4とも表記する。非特許文献6-8)等が発癌予測に使用されるが、その診断能は十分ではなく、より精密な層別化技術が必要である。
HBs抗原陽性患者は2019年時点で世界に2.96億人程度と推定され、年間約82万人がB型肝炎ウイルス(HBV)を原因とする肝硬変や肝癌で死亡している。核酸アナログ製剤(NUC)により血清中のHBV DNAを低下させることで肝癌発症のリスクは減じるが、HBV DNA低値例においても、発癌症例を認める(非特許文献9)。HBs抗原消失後の肝癌の発症率は0.0368/年である。一方でHBs抗原持続陽性例の肝癌の発症率は0.1957/年であり、有意に肝癌の発症率は高い(非特許文献10)。発癌リスクが高くなる因子として、年齢(40歳以上)、性別(男性)、高ウイルス量、飲酒者、肝癌の家族歴、HCV、HDV及び/又はHIVの共感染、肝線維化進展、肝線維化進展を反映する血小板数の低下、genotype C、コアプロモーター変異などが挙げられる(非特許文献11)。しかし、これらの因子を加味してもNUC投与下での肝癌発症の予測は困難であり、新たな肝発癌マーカーは臨床上重要である。
非ウイルス性肝疾患の多くは脂肪性肝疾患(いわゆる脂肪肝)である。脂肪性肝疾患は、肝細胞の5%以上に脂肪が蓄積した疾患をいう。脂肪性肝疾患はさらに非アルコール性脂肪性肝疾患(NAFLD)と二次性脂肪肝とに分類される。ここで非アルコール性とは、飲酒量をエタノールに換算して男性で30g/日、女性で20g/日未満をいう。NAFLDはさらに組織学的に肝細胞障害を伴わない非アルコール性脂肪肝(NAFL)と、組織学的に肝細胞障害及び炎症を伴う非アルコール性脂肪肝炎(NASH)とに分類される。二次性脂肪肝は、アルコール性、薬物性(アミオダロン、メトトレキサート、タモキシフェン、ステロイド、バルプロ酸、抗レトロウイルス薬など)、疾患性(C型肝炎(genotype3)、Wilson病、脂肪萎縮症、飢餓状態、非経口的栄養、Reye症候群、急性妊娠脂肪肝、HELLP症候群)、先天性代謝異常性(無βリポタンパク血症、ヘモクロマトーシス、α1アンチトリプシン欠損症、レシチンコレステロールアシルトランスフェラーゼ欠損症、ライソゾーム産生リパーゼ欠損症など)その他(膵頭十二指腸切除術後)に分類される。
非特許文献2:Zhang CH, et al. Liver Int. 2022 doi: 10.1111/liv.15251.
非特許文献3:Hikita H, et al. J Hepatol. 2012 Jul;57(1):92-100.
非特許文献4:Hikita H, et al. Cancer Prev Res (Phila). 2015 Aug;8(8):693-701.
非特許文献5:Janjua NZ et al., J Hepatol 2017;66:504-513.
非特許文献6:Watanabe T et al., J Med Virol 2020;92:3507-3515.
非特許文献7:Kanwal F, Singal AG, Gastroenterology 2019;157:54-64.
非特許文献8:Nagata H et al., J Hepatol 2017;67:933-939.
非特許文献9:Liaw YF, et al. N Engl J Med. 2004;351:1521-1531.
非特許文献10:Simonetti J, et al. Hepatology. 2010;51:1531-1537.
非特許文献11:Yim HJ, Lok AS. HEPATOLOGY 2006;43:S173-S181.
非特許文献12:Tokushige, K, et al. Hepatology Research.2021;51:1013-1025.
非特許文献13:Yoshiji, H. et al. J Gastroenterol, 2021;56:593-619.
非特許文献14:Angulo P, et al. Gastroenterology. 2015;149:389-97.
非特許文献15:Hagstrom H, et al. J Hepatol. 2017;67:1265-1273.
非特許文献16:Tateishi R, et al. J Gastroenterol. 2019;54:367-376.
非特許文献17:van Loon B, et al. DNA Repair (Amst) 2010;9:604-16
非特許文献18:Guichard C, et al. Nat Genet 2012;44:694-8.
非特許文献19:Han ES, et al. Physiol Genomics. 2008;34:112-26.
非特許文献20:Tsai VWW et al., Cell Metab 2018;28:353-368.
非特許文献21:Kim J et al., Nat Metab 2021;3:410-427.
非特許文献22:Kang SG et al., iScience 2021;24:102181
非特許文献23:Myojin Y et al., Gastroenterology 2021;160:1741-1754.
(1)被検者のGDF15レベルを測定する工程と、
(2)前記GDF15レベルと、肝癌発症リスクとを関連付ける工程と
を含む。
(2)前記GDF15レベルと、肝癌発症リスクとを関連付ける工程とを含む、GDF15の被検者の肝癌発症リスクを評価するためのバイオマーカーとしての使用を提供する。
本発明において、GDF15とは、トランスフォーミング成長因子(TGF)ベータスーパーファミリーに属するサイトカインで、全長アミノ酸308個からなるタンパク質である。胎盤に高発現するが、胎盤以外の正常組織では発現は弱い。炎症の際に急激に上向き調節される。ヒトGDF15タンパク質のアミノ酸配列、及び、GDF15mRNAのヌクレオチド配列は、それぞれ、NCBI Reference Sequence: NP_004855.2及びNM_004864.4として公表されており、自体公知の方法により単離することができる。
本発明の1つの実施態様は、慢性肝疾患を罹患した被検者の肝癌発症リスクを評価するための方法であって、
(1)前記被検者のGDF15タンパク質レベルを測定する工程と、
(2)前記GDF15タンパク質レベルと、肝癌発症リスクとを関連付ける工程と
を含む、方法を提供する。
本発明の1つの実施態様は、慢性肝疾患を罹患した被検者の肝癌発症リスクを評価するための方法であって、
(1)前記被検者のGDF15転写産物レベルを測定する工程と、
(2)前記GDF15転写産物レベルと、肝癌発症リスクとを関連付ける工程と
を含む、方法を提供する。
本発明は、本発明の方法に使用する、被検者のGDF15レベルを測定するためのキットを提供する。本発明のキットは、抗GDF15特異的抗体、及び/又は、GDF15転写産物を特異的に検出するためのプライマー対及びプローブを含む。本発明のキットに含まれる抗GDF15特異的抗体については、本明細書の「1.慢性肝疾患を罹患した被検者のGDF15タンパク質レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」に説明するとおりである。本発明のキットに含まれるGDF15転写産物を特異的に検出するためのプライマー対及びプローブについては、本明細書の「2.慢性肝疾患を罹患した被検者のGDF15転写産物レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」のセクションに説明するとおりである。
本発明は、本発明の方法によって慢性肝疾患を罹患した被検者の肝癌発症リスクを評価するための診断薬を提供する。本発明の診断薬は、抗GDF15抗体、及び/又は、GDF15転写産物を特異的に検出するためのプライマー対及び/又はプローブを含む。本発明の診断薬に含まれる抗GDF15特異的抗体については、本明細書の「1.慢性肝疾患を罹患した被検者のGDF15タンパク質レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」に説明するとおりである。本発明の診断薬に含まれるGDF15転写産物を特異的に検出するためのプライマー対及び/又はプローブについては、本明細書の「2.慢性肝疾患を罹患した被検者のGDF15転写産物レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」のセクションに説明するとおりである。
本発明は、GDF15の被検者の肝癌発症リスクを評価するためのバイオマーカーとしての使用を提供する。本発明のGDF15の使用に含まれる工程については、本明細書の「1.慢性肝疾患を罹患した被検者のGDF15タンパク質レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」、及び、「2.慢性肝疾患を罹患した被検者のGDF15転写産物レベルに基づいて該被検者の肝癌発症リスクを評価するための方法」のセクションに説明するとおりである。
A.材料及び方法
(1)調査対象の症例集団
Osaka Liver Forumに参加する26の医療機関のC型肝炎症例がベースライン時に登録され、日本肝臓学会のガイドライン(Hepatol Res 2020;50:791-816.)に準拠してインターフェロンフリーのDAA治療を受けた。B型肝炎ウイルス又はヒト免疫不全ウイルスの重複感染、非代償性肝硬変、又は、他の肝疾患(自己免疫性肝炎又は原発性胆汁性胆管炎等)の合併症例、肝移植後症例、又は、20歳未満の症例は登録から除外した。2017年12月までに合計2840名のC型肝炎症例が登録され、DAA治療を終了した。前記2840名の症例のうち、SVRを達成しなかった症例、ベースライン時の血清が入手不可能な症例、及び、肝癌治療歴のある症例を除いた残りの20施設1609名の症例が本発明の対象となった。このうち823名の症例はDAA治療前に肝生検を実施していた。その組織学的解析はMetavirスコアにより行われた。
本発明に参加する症例全員がインフォームドコンセント書面を提出した。本発明のデザインはヘルシンキ宣言を遵守する。本発明の患者情報及び試料の収集プロトコールは大阪大学附属病院臨床研究倫理審査委員会および各施設の倫理委員会で承認され(IRB 14148,14419,15080,15325,16314,16494,12449)、解析のプロトコールは大阪大学附属病院治験審査委員会で承認された(IRB No.17032)。
DAA治療は、asunaprevir及びdaclatasvir24週間、sofosbuvir及びledipasvir12週間、ombitasvir及び paritaprevir、ritonavir併用12週間、sofosbuvir及びribavirin12週間、elbasvir及び grazoprevir12週間のプロトコールで実施した。本発明においてSVRとは、治療終了24週間後にHCVのRNAレベルが検出不能であることをいう。症例全員が、HCV慢性感染症の治療に関する前記日本肝臓学会のガイドラインに準拠して処置された。
DAA治療開始前の症例は全員が超音波、CT及び/又はMRI検査を受診し、肝癌発症症例を除外した。DAA治療中の症例は血液学、生化学及びウイルス学的検査を含む血液検査を2週ごとに受けた。治療後の症例は超音波及び/又はCT/MRIを使う肝癌サーベイランスを6カ月ごとに行った。EASL-EORTC(European Association for the Study of the Liver - European Organisation for Research and Treatment of Cancer)、及び、AASLD(American Association for the Study of Liver Diseases)の推奨に従い、典型的な造影CT画像及び/又はMRIにより診断された(J Hepatol 2012;56:908-943.及びHepatology 2018;67:358-380.)。画像が肝癌の診断に限界がある場合には、腫瘍の標的生検が行われ、組織学的に診断された。フォローアップ開始日はDAA治療終了日である。エンドポイントは、肝癌が発生した日、又は、最終フォローアップの肝癌サーベイランス画像検査の日とした。全生存率のエンドポイントは、すべての原因で死亡した日、または最後のフォローアップを行った日とした。
登録された症例の血清は、プロスペクティブ・スタディ・プロトコルで決められた時点で、大阪大学の-80℃フリーザーに保管された。血清中のGDF15濃度は、メーカーのプロトコールに従って、ヒト酵素結合免疫吸着法(ELISA)キット(#DGD150, R&D systems, Minneapolis, MN)を用いて調べた。吸光度はVarioscan LUX(Thermo Scientific, Waltham, MA)で調べた。
肝組織RNAはRNeasyカラム(Qiagen, Hulsterweg, Germany)により抽出され、相補DNAに逆転写された。メッセンジャーRNA発現は、Thunderbird qPCR Master Mix(東洋紡、大阪、日本)及びTaqManプローブ(ヒトGDF15、Hs00171132_m1, human beta actin Hs 9999902_m3, Applied Biosystems, Waltham, MA)を用いる定量リアルタイム逆転写ポリメラーゼ連鎖反応により解析された。標的遺伝子発現はベータ-アクチンで正規化された。
パラメトリック及び非パラメトリック値の比較のための統計解析は、それぞれ、Student t検定及びMann-Whitney U検定で行った。one-way ANOVAと、その後のTurkey-Kramerの事後検定またはKruskal-Wallis検定が、それぞれ、パラメトリック及び非パラメトリック多重比較のために実施された。肝癌発症率の解析には、DAA終了日を指標とし、肝癌発症、死亡、または2020年12月31日以前の肝癌サーベイランスの最終日のいずれか早い方まで症例を追跡し、Kaplan-Meier曲線を示した。2群間の肝癌発症率の比較にはlog-rank検定を用いた。肝癌予測の解析にはロジスティック回帰分析を、肝癌発症リスクの比較にはCox比例ハザードモデルをそれぞれ用いた。解析にはPrism ver 8.4.2 for Windows(Graph Pad PRISM RRID; SCR_014242)を使用した。
(1)DAA治療後肝癌発症症例は血清GDF15レベルが肝癌非発症症例より高かった。
肝癌治療歴のない症例が,治療終了時及び治療終了後24週の両方の時点の保存血清が存在する導出(Derivation)コホートと、いずれかの時点の保存血清が存在しない検証(Varidation)コホートとに2分された。導出及び検証コホートの症例の詳細を図1に示す。
肝癌発症を予測するバイオマーカーとしての治療前の血清GDF15レベルを検討するために、肝癌発症に関連する治療前の変数をCox Hazardモデルによって解析した。FIB-4インデックスが3.25を超える(>3.25)症例が、過去の知見(Gastroenterology 2017;153:996-1005.e1001.、及び、Hepatology 2007;46:32-36.)に基づいて肝線維化進行症例と見なされた。他の変数は、中央値又は過去の知見(Clin Gastroenterol Hepatol 2014;12:1186-1195.)に基づいて2つの群に割り付けられた。単変量解析により、高齢、低血小板、高AST、高ALT、低アルブミン、低プロトロンビン活性、高AFP、高血清GDF15、高FIB-4インデックス及び高ALBIスコアは肝癌発症リスクの増大との関連が認められた(図7)。
導出コホートの研究では、肝癌発症リスクがGDF15レベル、AFP及びFIB-4インデックスを用いるスコアリングシステムによって層別化された。DAA治療前の血清しか利用可能でない751症例の検証コホートを用いて本スコアリングシステムを検証した。検証コホートでは、観察期間中にDAA治療後肝癌を発症したのは39症例であった(図11)。検証コホートでの肝癌発症率は、1年間で1.95%、2年間で4.54%、3年間で5.82%であった(図12)。導出コホートと検証コホートとでは累積肝癌発症率に有意差は認められなかった(p=0.57)。低GDF15群、低AFP群及び低FIB-4インデックス群は、累積肝癌発症率が、それぞれ、高GDF15群、高AFP群及び高FIB-4インデックス群より有意に低かった(図13A~C)。
A.材料及び方法
(1)調査対象の症例集団
本実施例の調査対象は、長期経過が調査可能な保存血清のある核酸アナログ(NUC)投与症例である。ここで、保存血清の選択基準は、保存血清ポイント(複数存在する場合は該当する中で最も古い血清についての保存血清ポイント)で8か月以上のNUC投与歴があること、及び、保存血清ポイントで血清HBV DNA 3.0 logIU/ml未満の症例であることである。ただし、血清ポイント時点で肝癌既往歴のある患者と、B型肝炎以外の肝疾患の合併する患者とを除外する。
本発明のデザインはヘルシンキ宣言を遵守する。本発明の患者情報及び試料の収集、解析プロトコールは大阪大学附属病院臨床研究倫理審査委員会で承認され(IRB 17032)、大阪大学医学部附属病院を含む各施設で実施許可を得ている。
核酸アナログ製剤(NUC)治療のプロトコールは、日本肝臓学会編『B型肝炎治療ガイドライン』(第1版)2013年4月~(第3.4版)2021年5月(https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v3.4.pdf)、同英語版(Hepatology Research, 2020; 50: 892-923.)などのうち、その時期に利用可能なガイドラインに準拠して治療された。具体的にはNUC治療開始後は、その時期に使用可能なNUCの内服を継続した。
HBVについてNUC投与による治療中の患者のフォローアップ及び肝癌サーベイランスは、HCVの抗ウイルス治療患者のフォローアップ及び肝癌サーベイランスに準じて実施された。
HBVについてNUC投与による治療中の患者の血清検査及び統計解析は、HCVの抗ウイルス治療患者の血清検査及び統計解析と同様に実施された。
(1)HBVについてNUC投与による治療中の肝癌発症症例は血清GDF15レベルが肝癌非発症症例より高かった。
NUC投与による治療中の症例のGDF15の血清濃度の散布図、患者背景及び今回のコホート全体での肝癌発症率の経時変化を示すグラフを、それぞれ、図16、図17及び図18に示す。図16及び図17に示すとおり、GDFの血清濃度のコホート全体での中央値及び25%-75%区間は0.833ng/mL及び0.555-1.206ng/mLであった。
A.材料及び方法
(1)調査対象の症例集団
本実施例の調査対象は、2012年から2020年に肝生検でNAFLDと診断された症例のうち、その後の経過が調査可能な肝生検時の保存血清のある症例である。ただし、血清ポイント時点で肝癌既往歴のある患者と、NAFLD以外の肝疾患の合併する患者とを除外する。
本発明に参加する症例全員がインフォームドコンセント書面を提出した。本発明のデザインはヘルシンキ宣言を遵守する。本発明の患者情報及び試料の収集、解析プロトコールは大阪大学附属病院臨床研究倫理審査委員会で承認され(IRB 17032、19551)、大阪大学医学部附属病院を含む各施設で実施許可を得ている。
非アルコール性脂肪肝(NAFL)及び非アルコール性脂肪肝炎(NASH)については、NAFLD/NASH診療ガイドライン2020(日本消化器病学会・日本肝臓学会編、改訂第2版、2020年11月発行、南江堂(https://www.jsge.or.jp/guideline/guideline/pdf/nafldnash2020.pdf))、同英語版(Tokushige, K. et al. HepatologyResearch.2021;51:1013-1025.及びTokushige, K. et al. Journal of Gastroenterology 2021;56: 951-963.)どのうち、その時期に利用可能なガイドラインに準拠して治療された。
NAFL又はNASHを罹患している患者のフォローアップ及び肝癌サーベイランスは、HCVの抗ウイルス治療患者のフォローアップ及び肝癌サーベイランスに準じて実施された。
NAFL又はNASHを罹患している患者の血清検査及び統計解析は、HCVの抗ウイルス治療患者の血清検査及び統計解析と同様に実施された。
図26は、NAFL又はNASHを罹患している患者のGDF15の血清濃度の散布図である。図26の散布図では、黒丸が肝癌非発症例、白丸が肝癌発症例を表す。発症した肝癌6症例中5例は、原発性肝細胞癌(HCC)であったが、矢印で示した1例は胆管細胞癌(CCC)であった。図27は、NAFL又はNASHを罹患している患者の患者背景を示す表である。図28は、NAFLを罹患している患者とNASHを罹患している患者とに群分けした患者背景を示す表である。図28に示すとおり、NAFLを罹患している患者のGDFの血清濃度のコホート全体での中央値及び25%-75%区間は1.07ng/mL及び0.69-1.49ng/mLであり、NASHを罹患している患者のGDFの血清濃度のコホート全体での中央値及び25%-75%区間は1.41ng/mL及び0.98-1.94ng/mLであった。図29は、AFL又はNASHを罹患している患者コホート全体での肝癌の発症率の経時変化を示すグラフである。
大垣市民病院183例を追加してさらに検討した。
(1)調査対象の症例集団
本実施例の調査対象は、2005年から2020年に肝生検でNAFLDと診断された症例のうち、その後の経過が調査可能な肝生検時の保存血清のある症例である。ただし、血清ポイント時点で肝癌既往歴のある患者と、NAFLD以外の肝疾患の合併する患者とを除外する。
本発明に参加する症例全員がインフォームドコンセント書面を提出した。本発明のデザインはヘルシンキ宣言を遵守する。本発明の患者情報及び試料の収集、解析プロトコールは大阪大学附属病院臨床研究倫理審査委員会で承認され(IRB 17032)、大阪大学医学部附属病院と大垣市民病院で実施許可を得ている。
NAFLDの治療は実施例3と同様に行った。
NAFLDを罹患している患者のフォローアップ及び肝癌サーベイランスは、HCVの抗ウイルス治療患者のフォローアップ及び肝癌サーベイランスに準じて実施された。
NAFLDを罹患している患者の血清検査及び統計解析は、HCVの抗ウイルス治療患者の血清検査及び統計解析と同様に実施された。
図35-1及び図35-2は、それぞれ、大垣市民病院及び観察期間を延長した実施例3のコホートの患者背景を示す。
Claims (14)
- (1)被検者のGDF15レベルを測定する工程と、
(2)前記GDF15レベルと、肝癌発症リスクとを関連付ける工程とを含む、
被検者の肝癌発症リスクを評価するための方法。 - 前記被検者は、C型肝炎ウイルス(HCV)持続陰性化(SVR)を達成した被検者、B型肝炎におけるNUC投与中の被検者、及びNAFLDを発症した被検者からなる群から選択される少なくとも1種類の被検者である、請求項1に記載の方法。
- 前記被検者のGDF15レベルが、予め設定したカットオフ値以上の場合には前記被検者の肝癌発症リスクが高いことの指標となり、前記カットオフ値未満の場合には前記被検者の肝癌発症リスクが低いことの指標となる、請求項1又は2に記載の方法。
- GDF15レベルは、血清又は血漿中のGDF15タンパク質のレベル、及び/又は、肝組織又は循環血中のGDF15転写産物のレベルである、請求項1ないし3のいずれか1項に記載の方法。
- 前記カットオフ値は、前記GDF15レベルの統計解析又はROC解析に基づいて設定される、請求項3に記載の方法。
- 前記カットオフ値は、前記被検者のGDF15レベルの中央値か、前記被検者のROC曲線のYoudenインデックスが最大値となるGDF15レベルの数値かである、請求項5に記載の方法。
- 前記被検者はHCVのSVRを達成した被検者であり、前記GDF15レベルのカットオフ値はGDF15タンパク質の血清濃度約1400pg/mLであるか、前記被検者はB型肝炎におけるNUC投与中の被検者であり、前記GDF15レベルのカットオフ値はGDF15タンパク質の血清濃度約845pg/mLであるか、前記被検者はNAFLDを発症した被検者であり、前記GDF15レベルのカットオフ値はGDF15タンパク質の血清濃度約2000pg/mLである、請求項6に記載の方法。
- 前記血清中のGDF15タンパク質のレベルはELISA法によって決定される、請求項1ないし7のいずれか1項に記載の方法。
- 前記被検者はHCVのSVRを達成した被検者であり、前記血清中のGDF15レベルのカットオフ値は約1400pg/mLであり、前記肝癌発症リスクを判定する工程では、AFP及びFIB-4インデックスのカットオフ値を更に組み合わせて判定する、請求項7又は8に記載の方法。
- 前記AFP及びFIB-4インデックスのカットオフ値は、それぞれ、5ng/mL及び3.25である、請求項9に記載の方法。
- 抗GDF15特異的抗体、及び/又は、GDF15転写産物を特異的に検出するためのプライマー対若しくはプローブを含む、請求項1ないし10のいずれか1項に記載の方法に使用するための被検者のGDF15レベルを測定するためのキット。
- 抗GDF15特異的抗体、及び/又は、GDF15転写産物を特異的に検出するためのプライマー対若しくはプローブを含む、請求項1ないし10のいずれか1項に記載の方法に使用するための診断薬。
- (1)被検者のGDF15レベルを測定する工程と、
(2)前記GDF15レベルと、肝癌発症リスクとを関連付ける工程とを含む、
被検者の肝癌発症リスクを評価するためのバイオマーカーとしてのGDF15の使用。 - 前記被検者は、C型肝炎ウイルス(HCV)持続陰性化(SVR)を達成した被検者、B型肝炎におけるNUC投与中の被検者、及びNAFLDを発症した被検者からなる群から選択される少なくとも1種類の被検者である、請求項13に記載の使用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023538551A JPWO2023008427A1 (ja) | 2021-07-26 | 2022-07-26 | |
CN202280052589.2A CN117957445A (zh) | 2021-07-26 | 2022-07-26 | 慢性肝疾病中的肝癌发生的诊断标志物 |
KR1020247006286A KR20240046521A (ko) | 2021-07-26 | 2022-07-26 | 만성 간 질환에서 간암 발증의 진단 마커 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021121873 | 2021-07-26 | ||
JP2021-121873 | 2021-07-26 | ||
JP2022084132 | 2022-05-23 | ||
JP2022-084132 | 2022-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023008427A1 true WO2023008427A1 (ja) | 2023-02-02 |
Family
ID=85087709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/028776 WO2023008427A1 (ja) | 2021-07-26 | 2022-07-26 | 慢性肝疾患における肝発癌の診断マーカー |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2023008427A1 (ja) |
KR (1) | KR20240046521A (ja) |
WO (1) | WO2023008427A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007192557A (ja) * | 2006-01-17 | 2007-08-02 | Perseus Proteomics Inc | C型肝炎患者の肝疾患の重篤化をモニターする方法および肝癌の診断方法 |
JP2010243406A (ja) * | 2009-04-08 | 2010-10-28 | F Hoffmann La Roche Ag | Afpおよびpivka−iiの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法 |
JP2012103211A (ja) * | 2010-11-12 | 2012-05-31 | Mitsubishi Chemical Medience Corp | 肝臓がん発症の検出又はリスクの予測方法 |
JP2012179047A (ja) * | 2011-02-10 | 2012-09-20 | Institute Of Physical & Chemical Research | 肝細胞癌への進展予測マーカー |
CN107462720A (zh) * | 2017-06-19 | 2017-12-12 | 上海长海医院 | 一种opn、gdf15、nse、trap5和opg联合诊断试剂盒 |
CN109781984A (zh) * | 2019-01-29 | 2019-05-21 | 广州瑞博奥生物科技有限公司 | 一种同时定量检测多个肝癌标志物的抗体芯片试剂盒 |
CN111393526A (zh) * | 2020-03-30 | 2020-07-10 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
JP2020528138A (ja) * | 2017-08-21 | 2020-09-17 | ソウル ナショナル ユニバーシティ ホスピタル | 肝疾患予測又は診断用組成物及びこれを用いた肝疾患予測又は診断方法 |
JP2021121873A (ja) | 2016-06-20 | 2021-08-26 | 株式会社東芝 | 加熱装置、画像形成装置 |
JP2022084132A (ja) | 2020-11-26 | 2022-06-07 | 大和製衡株式会社 | 組合せ秤 |
-
2022
- 2022-07-26 JP JP2023538551A patent/JPWO2023008427A1/ja active Pending
- 2022-07-26 WO PCT/JP2022/028776 patent/WO2023008427A1/ja active Application Filing
- 2022-07-26 KR KR1020247006286A patent/KR20240046521A/ko unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007192557A (ja) * | 2006-01-17 | 2007-08-02 | Perseus Proteomics Inc | C型肝炎患者の肝疾患の重篤化をモニターする方法および肝癌の診断方法 |
JP2010243406A (ja) * | 2009-04-08 | 2010-10-28 | F Hoffmann La Roche Ag | Afpおよびpivka−iiの測定値を特徴値とした識別関数を利用する、肝臓癌および慢性肝疾患の病態進行度の検出方法 |
JP2012103211A (ja) * | 2010-11-12 | 2012-05-31 | Mitsubishi Chemical Medience Corp | 肝臓がん発症の検出又はリスクの予測方法 |
JP2012179047A (ja) * | 2011-02-10 | 2012-09-20 | Institute Of Physical & Chemical Research | 肝細胞癌への進展予測マーカー |
JP2021121873A (ja) | 2016-06-20 | 2021-08-26 | 株式会社東芝 | 加熱装置、画像形成装置 |
CN107462720A (zh) * | 2017-06-19 | 2017-12-12 | 上海长海医院 | 一种opn、gdf15、nse、trap5和opg联合诊断试剂盒 |
JP2020528138A (ja) * | 2017-08-21 | 2020-09-17 | ソウル ナショナル ユニバーシティ ホスピタル | 肝疾患予測又は診断用組成物及びこれを用いた肝疾患予測又は診断方法 |
CN109781984A (zh) * | 2019-01-29 | 2019-05-21 | 广州瑞博奥生物科技有限公司 | 一种同时定量检测多个肝癌标志物的抗体芯片试剂盒 |
CN111393526A (zh) * | 2020-03-30 | 2020-07-10 | 中国人民解放军第四军医大学 | 抗gdf15中和性单克隆抗体及其应用 |
JP2022084132A (ja) | 2020-11-26 | 2022-06-07 | 大和製衡株式会社 | 組合せ秤 |
Non-Patent Citations (63)
Title |
---|
"Clinical Practice Guidelines for Hepatocellular Carcinoma", October 2017 |
"EASL recommendations on treatment of hepatitis C: Final update of the series", J HEPATOL, vol. 73, 2020, pages 1170 - 1218 |
"Guidelines for the Management of Hepatitis B Virus Infection", April 2013 |
"Guidelines for the Management of Hepatitis C Virus Infection", July 2020 |
"NAFLD/NASH SINRRYO GUIDELINE 2020 (NAFLD/NASH clinical practice guideline 2020", November 2020, NANKODO CO., LTD. |
"NCBI", Database accession no. NM_004864.4 |
ANGULO P ET AL., GASTROENTEROLOGY, vol. 149, 2015, pages 389 - 97 |
CANCER, vol. 3, 1950, pages 32 - 35 |
CHEN JUANJUAN, TANG DONGLING, XU CHU, NIU ZHILI, LI HUAN, LI YAN, ZHANG PINGAN: "Evaluation of Serum GDF15, AFP, and PIVKA-II as Diagnostic Markers for HBV-Associated Hepatocellular Carcinoma", LABORATORY MEDICINE, AMERICAN SOCIETY OF CLINICAL PATHOLOGISTS, CHICAGO, IL, US, vol. 52, no. 4, 1 July 2021 (2021-07-01), US , pages 381 - 389, XP093029561, ISSN: 0007-5027, DOI: 10.1093/labmed/lmaa089 * |
CLIN GASTROENTEROL HEPATOL, vol. 12, 2014, pages 1186 - 1195 |
DIG LIVER DIS, vol. 51, 2019, pages 681 - 688 |
ENGVALL E, METHODS IN ENZYMOL., vol. 70, 1980, pages 419 - 439 |
FURIHATA CHIE, YOU XINYUE, TOYODA TAKESHI, OGAWA KUMIKO, SUZUKI TAKAYOSHI: "Using FFPE RNA-Seq with 12 marker genes to evaluate genotoxic and non-genotoxic rat hepatocarcinogens", GENES AND ENVIRONMENT, vol. 42, no. 1, 1 December 2020 (2020-12-01), XP093029551, DOI: 10.1186/s41021-020-00152-4 * |
FURIHATA CHIE: "Attempts at Organ-specific In Vivo Short-term Tests for Environmental Mutagens and Carcinogens in Rodent Liver and Stomach", GENES AND ENVIRONMENT, vol. 35, no. 2, 1 January 2013 (2013-01-01), pages 31 - 45, XP093029549, ISSN: 1880-7046, DOI: 10.3123/jemsge.35.31 * |
GASTROENTEROLOGY, vol. 153, 2017, pages 996 - 1005 |
GASTROENTEROLOGY, vol. 155, no. 6, December 2018 (2018-12-01), pages 1828 - 1837 |
GHANY MG, MORGAN TR.: "Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Viral infection", HEPATOLOGY, vol. 71, 2020, pages 686 - 721, XP071566118, DOI: 10.1002/hep.31060 |
GUICHARD C ET AL., NAT GENET, vol. 44, 2012, pages 694 - 8 |
HAGSTROM H ET AL., J HEPATOL., vol. 67, 2017, pages 1265 - 1273 |
HAN ES ET AL., PHYSIOL GENOMICS, vol. 34, 2008, pages 112 - 26 |
HELD CA ET AL., GENOME RESEARCH, vol. 6, 1996, pages 986 - 994 |
HEPATOL RES, vol. 50, 2020, pages 791 - 816 |
HEPATOLOGY RESEARCH, vol. 50, 2020, pages 892 - 923 |
HEPATOLOGY, vol. 46, 2007, pages 32 - 36 |
HEPATOLOGY, vol. 67, 2018, pages 358 - 380 |
HIKITA H ET AL., CANCER PREV RES (PHILA, vol. 8, no. 8, August 2015 (2015-08-01), pages 693 - 701 |
HIKITA H ET AL., J HEPATOL., vol. 57, no. 1, July 2012 (2012-07-01), pages 92 - 100 |
HIKITA, HAYATO: "Examination of the usefulness of serum GDF15 as a biomarker for liver cancer after hepatitis C SVR", KANO-ACTA HEPATOLOGICA JAPAN, NIHON KANZO KYOKAI, TOKYO,, JP, vol. 62, no. 3, 25 November 2021 (2021-11-25), JP , pages A683, XP009542956, ISSN: 0451-4203 * |
J HEPATOL, vol. 56, 2012, pages 908 - 943 |
JANJUA NZ ET AL., J HEPATOL, vol. 68, 2017, pages 933 - 939 |
KANG SG ET AL., ISCIENCE, vol. 24, 2021, pages 102181 |
KANWAL FSINGAL AG, GASTROENTEROLOGY, vol. 157, 2019, pages 54 - 64 |
KIM J ET AL., NAT METAB, vol. 3, 2021, pages 410 - 427 |
LEE HO-YEOP, NGA HA THI, TIAN JINGWEN, YI HYON-SEUNG: "Mitochondrial Metabolic Signatures in Hepatocellular Carcinoma", CELLS, vol. 10, no. 8, 1 January 2021 (2021-01-01), pages 1901, XP093029568, DOI: 10.3390/cells10081901 * |
LIAW YF ET AL., N ENGL J MED., vol. 351, 2004, pages 1521 - 1531 |
LIU KAIKUN, ZHA BIN-SHAN, LIU YUE-FANG, ZHU JIN, FENG ZHEN-QING, ZHANG JIAN-PING: "Expression of GDF15 in rat early-stage hepatocellular carcinoma and human small hepatocellular carcinoma", ACTA UNIVERSITATIS MEDICINALIS NANJING (NATURAL SCIENCE) [JOURNAL OF NANJING MEDICAL UNIVERSITY (NATURAL SCIENCE)], NANJING UNIVERSITY, CN, vol. 28, no. 4, 1 January 2008 (2008-01-01), CN , pages 439 - 444, XP093029560, ISSN: 1007-4368 * |
MOHAB H. HALIM, NOUR A. ABDULLA, ABDELKARIM KAMEL, NABILA ABD EL MAKSOUD, HALLA M. RAGAB: "Significance of growth differentiation factor 15 in chronic HCV patients", JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY, vol. 15, no. 2, 1 December 2017 (2017-12-01), pages 403 - 407, XP055615825, ISSN: 1687-157X, DOI: 10.1016/j.jgeb.2017.08.004 * |
MYOJIN Y ET AL., GASTROENTEROLOGY, vol. 160, 2021, pages 1741 - 1754 |
MYOJIN YUTA, HAYATO HIKITA, YUKI TAHATA, AKIRA DOI, SEIYA KATO, YOICHI SASAKI, KUMIKO SHIRAI, SADATSUGU SAKANE, RYOKO YAMADA, TAKA: "Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 55, no. 4, pages 422 - 433, XP093029572, DOI: 10.1111/apt.16691 * |
MYOJIN, Y. ET AL., ALIMENT PHARMACOL THER., vol. 55, 2022, pages 422 - 433 |
MYOJIN, YUTA: "Recent advances in research on liver sinusoidal cells. III. Role of sinusoidal parietal cells in tumor microenvironment Influence of hepatic stellate cells in liver cancer microenvironment", KAN TAN SUI JAPAN, ARCMEDIUM, JP, vol. 82, no. 4, 28 April 2021 (2021-04-28), JP , pages 555 - 560, XP009543324, ISSN: 0389-4991 * |
MYOJIN, YUTA: "Serum GDF15 is a biomarker of novel carcinogenicity prediction for chronic hepatitis C liver disease", KANO-ACTA HEPATOLOGICA JAPAN, NIHON KANZO KYOKAI, TOKYO,, JP, vol. 62, no. suppl. 2, 30 September 2021 (2021-09-30), JP , pages A494, XP009542954, ISSN: 0451-4203 * |
MYOJIN, YUTA: "SST5-3 Hepatic stellate cell autophagy promotes HCC growth via GDF15", ABSTRACTS OF THE 79TH ANNUAL MEETING OF THE JAPANESE CANCER ASSOCIATION; HIROSHIMA, JAPAN; OCTOBER 1‐3, 2020, vol. 79, 30 September 2020 (2020-09-30) - 3 October 2020 (2020-10-03), pages 1066, XP009543326 * |
SAGNELLI E ET AL., INFECTION, vol. 48, no. 1, February 2020 (2020-02-01), pages 7 - 17 |
SAMBROOK, JRUSSELL, DW: "Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
SASAKI HAJIME, HIROSHI KITAJIMA, TAKESHI NIINUMA, HIDEKI WAKASUGI, KAZUYA ISHIGURO, AKIRA YOROZU, GOUTA SUDO, TOMO HATAHIRA, NORIY: "Analysis of the anti-tumor mechanism of BRD4 inhibition in hepatocellular carcinoma", vol. 88, 1 December 2019 (2019-12-01), pages 21 - 35, XP093029565, DOI: 10.15114/smj.88.21 * |
SIMONETTI J ET AL., HEPATOLOGY, vol. 51, 2010, pages 1531 - 1537 |
TAKASHI WATANABE; TAKAYOSHI SUZUKI; MASAKATSU NATSUME; MADOKA NAKAJIMA; KAZUNORI NARUMI; SHUICHI HAMADA; TOMOHIRO SAKUMA; AKIKO KO: "Discrimination of genotoxic and non-genotoxic hepatocarcinogens by statistical analysis based on gene expression profiling in the mouse liver as determined by quantitative real-time PCR", MUTATION RESEARCH. GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, ELSEVIER, AMSTERDAM, NL, vol. 747, no. 2, 29 April 2012 (2012-04-29), NL , pages 164 - 175, XP028401672, ISSN: 1383-5718, DOI: 10.1016/j.mrgentox.2012.04.011 * |
TATEISHI R ET AL., J GASTROENTEROL., vol. 54, 2019, pages 367 - 376 |
TERESA A. ZIMMERS ; XIAOLING JIN ; JUAN C. GUTIERREZ ; CARY ACOSTA ; IAIN H. MCKILLOP ; ROBERT H. PIERCE ; LEONIDAS G. KONIARIS: "Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER, BERLIN, DE, vol. 134, no. 7, 22 January 2008 (2008-01-22), Berlin, DE , pages 753 - 759, XP019630698, ISSN: 1432-1335 * |
TIAN, XIA: "Study on diagnostic value of serum GDF-15, GP73 and AFP in hepatocellular carcinoma", JIANYAN YIXUE YU LINCHUANG = LABORATORY MEDICINE AND CLINIC, CHONGQING SHI WEISHENG XINXI ZHONGXIN, CN, vol. 18, no. 16, 31 July 2021 (2021-07-31), CN , pages 2438 - 2440, XP009542952, ISSN: 1672-9455 * |
TOKUSHIGE, K ET AL., HEPATOLOGY RESEARCH, vol. 51, 2021, pages 1013 - 1025 |
TOKUSHIGE, K. ET AL., HEPATOLOGYRESEARCH, vol. 51, 2021, pages 1013 - 1025 |
TOKUSHIGE, K. ET AL., JOURNAL OF GASTROENTEROLOGY, vol. 56, 2021, pages 951 - 963 |
TSAI VWW ET AL., CELL METAB, vol. 28, 2018, pages 353 - 368 |
VAN LOON B ET AL., DNA REPAIR (AMST, vol. 9, 2010, pages 604 - 16 |
WATANABE T ET AL., J MED VIROL, vol. 92, 2020, pages 3507 - 3515 |
WEIS JH ET AL., TRENDS IN GENETICS, vol. 8, 1992, pages 263 - 264 |
XIONG XIANGYU; YUAN JUPENG; ZHANG NASHA; ZHENG YAN; LIU JIBING; YANG MING: "Silencing of lncRNA PVT1 by miR-214 inhibits the oncogenic GDF15 signaling and suppresses hepatocarcinogenesis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 521, no. 2, 31 October 2019 (2019-10-31), Amsterdam NL , pages 478 - 484, XP085980849, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2019.10.137 * |
XIUYING LIU, XIUMEI CHI, QIAOLING GONG, LEI GAO, YUQIANG NIU, XIAOJING CHI, MIN CHENG, YOUHUI SI, MAORONG WANG, JIN ZHONG, JUNQI N: "Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma", PLOS ONE, vol. 10, no. 5, pages e0127518, XP055615813, DOI: 10.1371/journal.pone.0127518 * |
YIM HJLOK AS, HEPATOLOGY, vol. 43, 2006, pages S173 - S181 |
YOSHIJI, H. ET AL., J GASTROENTEROL, vol. 56, 2021, pages 593 - 619 |
ZHANG CH ET AL., LIVER INT., 2022 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2023008427A1 (ja) | 2023-02-02 |
KR20240046521A (ko) | 2024-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101032607B1 (ko) | 간암 진단용 단백질성 마커 | |
US10670610B2 (en) | Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome | |
US20110189698A1 (en) | Protein Biomarkers and Methods for Diagnosing Kawasaki Disease | |
JP6401702B2 (ja) | 炎症性肝疾患の診断のための方法および組成物 | |
WO2017181367A1 (en) | Methods and compositions for prognosing preterm birth | |
US10859573B2 (en) | Nourin molecular biomarkers diagnose angina patients with negative troponin | |
JP6691617B2 (ja) | 子癇前症の評価を提供するための方法及び組成物 | |
US20100279878A1 (en) | Biomarkers for Septic Shock Patients | |
JP3538381B2 (ja) | 結腸癌を診断し、モニターし、そして病期決定する新規方法 | |
CN113234830B (zh) | 用于肺癌诊断的产品及用途 | |
JP3469551B2 (ja) | 子宮内膜癌および子宮癌の検出及び監視のための新規な方法 | |
KR102302682B1 (ko) | 우울증 진단용 바이오마커 및 이의 용도 | |
CN109891239B (zh) | 用于提供子痫前期评估和预测早产的方法和试剂盒 | |
EP3346270A1 (en) | Composition for diagnosing infectious diseases or infectious complications by using tryptophanyl-trna synthetase and method for detecting diagnostic marker | |
CN113502326B (zh) | 基于生物标志物的肺动脉高压的诊断产品及其应用 | |
CN110656169B (zh) | 心房颤动的诊断标志物 | |
WO2023008427A1 (ja) | 慢性肝疾患における肝発癌の診断マーカー | |
CN109891241B (zh) | 能够进行糖尿病性肾病的早期病情的特异性诊断的检查方法 | |
EP4382912A1 (en) | Diagnostic marker for hepatic cancer development in chronic hepatic disease | |
TWI598444B (zh) | 用以評估乳癌罹患風險之方法及基因標記 | |
JP7239139B2 (ja) | 肝硬変の診断方法、非アルコール性脂肪肝炎及び肝細胞がんの合併症の診断方法並びに非アルコール性脂肪肝炎及び食道胃静脈瘤の合併症の診断方法 | |
CN117957445A (zh) | 慢性肝疾病中的肝癌发生的诊断标志物 | |
WO2024004675A1 (ja) | 肝臓癌の発症可能性を検査する方法 | |
KR101815253B1 (ko) | 간 섬유화 진단용 바이오마커 cxcl14 | |
CN116287207B (zh) | 生物标志物在诊断心血管相关疾病中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22849488 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023538551 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280052589.2 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20247006286 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022849488 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022849488 Country of ref document: EP Effective date: 20240226 |